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ABSTRACT 
 
 
The Cardiovascular diseases (CVDs) continue to be the leading cause of 
morbidity and mortality worldwide. The most common form of CVDs is occlusion of 
blood flow thus limiting blood supply to specific tissues or organs. Atherosclerosis is a 
leading cause of coronary heart disease and stroke, which were responsible for more than 
25% of deaths in 2004.  
The demand for vascular graft is huge. In United States alone, approximately 
500,000 coronary artery bypass graft surgeries are performed annually. Synthetic 
polymers such as Dacron and ePTFE have been successfully applied in large diameter 
blood vessel prosthesis; however, for small diameter (inner diameter < 6mm) blood 
vessel replacement, both performed poorly in small diameter indications. Autologous 
saphenous vein or internal mammary artery remains the gold standard. However, 
autologous vessel is not available in about 1/3 of the patients.  
We proposed a novel biological scaffold based on decellularization of porcine 
arteries. Decellularized arterial scaffolds were further stabilized with penta-galloyl 
glucose (PGG) to render it more resistant to rapid in vivo biodegradation. The resultant 
scaffolds had good mechanical properties in burst pressure and vascular compliance. 
Subdermal implantation study showed that our novel scaffolds were biocompatible, 
inductive to host cell repopulation and had good remodeling potential.   
A dynamic cell seeding device which is capable of utilizing three different 
mechanisms was designed and built to endothelialize luminal surface of grafts. Of three 
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mechanisms, electrical field and hydrostatic pressure seeding methods resulted in overall 
good cell coverage, while chemotaxis was the least efficient.  
We further developed a pulsatile vascular bioreactor to test endothelial cells 
retention under pulsatile flow. Grafts expanded and recoiled in response to the pulsatile 
flow created by the pinch valve periodically opening/closing at 1Hz. We found that 
seeded endothelial cells could withstand to 20h of pulsation and stayed alive, as shown in 
the DiffQuik and Live/Dead staining results. 
In collaboration with researchers in Japan & South Africa, we tested the 
functionality of our PGG-stabilized scaffolds using animal circulation models. Vascular 
graft of about 5 cm long was anastomosed to host artery in end-to-end fashion. 
Preliminary data showed that our novel acellular vascular scaffolds were very inductive 
to host cell repopulation. Heparinized grafts remained patent after 7 days. 
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 CHAPTER ONE 
 
INTRODUCTION 
 
 
1.1 Atherosclerosis and Treatments 
1.1.1 Arterial Occlusive Disease 
Cardiovascular disorders (CVDs) are a group of disorders that affect heart and 
blood vessels. CVDs include coronary heart diseases, cerebrovascular diseases, 
peripheral arterial diseases, rheumatic heart diseases, deep vein thrombosis and 
pulmonary embolisms and congenital heart diseases[1].   
CVDs continue to be the leading cause of morbidity and mortality worldwide. 
According to statistics from the American Heart Association, CVDs claim about as many 
lives each year as cancer, chronic lower respiratory diseases, accidents and diabetes 
mellitus combined [2]. In 2004, about 57% of all deaths were CVDs-related. On average, 
one American dies of CVDs in every 37 seconds [2]. CVDs impose huge loading to the 
medical care system. It is estimated that the direct and indirect cost of CVD in the United 
States for 2008 is $448.5 billion [2] (Fig. 1). 
The most common form of CVDs is occlusion of blood flow thus limiting blood 
supply to specific tissues or organs. When blood supply is limited, tissues begin to die 
due to insufficient oxygen and nutrients. For example, if there is unsatisfying blood 
supply to heart, cardiomyocytes begin to undergo necrosis thus leading to angina or even 
heart attack; when the blood supply to the brain is limited due to embolism, it causes 
stroke. Atherosclerosis is a leading cause of coronary heart disease and stroke, which 
were responsible for more than 25% of deaths in 2004 [2].   
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 Sedentary life style and high fat/cholesterol diet all contribute to the CVDs 
pathological progression. Fatty substances build up on the wall of blood vessels gradually 
and lead to hardening and narrowing of blood vessel (Fig. 2). This pathological 
progression may start as early as adolescence. As we age, the situation gets worse and 
may lead to narrowing or occlusion of arteries. 
 
Fig. 1 Cardiovascular Diseases and Other Major Causes of Death for All Males and 
Females [2] 
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Fig. 2 Atherosclerosis; lipids, cholesterol, cellular debris, calcium and other substances 
build up in the inner lining of artery forming plaque, and the plaque gradually 
occludes blood flow[3]. 
 
1.1.2 Treatment Options 
Endovascular Surgical Intervention [4-6] 
Atherosclerotic plaque could be removed by surgical methods. Endovascular 
surgery, also known as minimally invasive vascular surgery, unlike traditional open 
procedures which require a larger incision, surgical exposure of target tissue/organ and a 
longer recuperation time involves operating from the inside through a small puncture 
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wound or incision. Medical devices and drugs are delivered to the target site with remote 
catheter-mediated actions.  
 
Balloon Angioplasty and Vascular stent 
Percutaneous translumnial angioplasty is an outpatient procedure performed under 
local anesthesia, commonly used in conjunction with stents[4, 7, 8]. Having a high 
success rate of more than 90%, and fast recovery, it is appropriate for single vessel 
disease[4]. When deployed, balloon expands to compress plaque to effect repacking and 
further luminal expansion. High pressure balloon mounted on catheter is designed to 
dilate calcified plaques. To prevent elastic recoil (acute closure), a stent is placed to 
provide mechanical support (Fig.3)[7]. However, re-occlusion (restenosis) may occur due 
to excess tissue proliferation (intimal hyperplasia) in respond to mechanical injury that 
came along with stent deployment. In addition, early thrombosis may constitute another 
problem, anti-platelet treatment is needed[4]. 
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Fig. 3 Coronary Balloon Angioplasty (left) and Stent Placement (right) 
[http://www.nhlbi.nih.gov/health/dci/Diseases/Angioplasty/Angioplasty_howdone.html] 
 
Atherectomy  
Atherectomy is the process of mechanically shaving and removing plaque 
material from atherosclerotic vessel. Directional atherectomy[4, 9] (Fig.4) is intended to 
remove soft, uncalcified plaques. A partially open metal capsule containing small motor-
driven rotating blades is placed in stenosed region with a catheter. When balloon inflates, 
it pushes blade toward plaque to be cut off. Shaved debris is stored in distal end of 
catheter. Catheter is rotated to remove another segment of the plaque. Rotational 
atherectomy[4, 9] (Fig.5) is used to remove very long, calcified plaques. Compressed air 
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drives small diamond blades to rotate at 150,000 rpm to shave off plaque. Debris particles 
are small enough to prevent distal embolization. The underlying media remains intact. 
Transluminal extraction catheter[4, 9] (Fig.6) contains tiny rotating blades and a hollow 
tube which collects shave-off debris by vacuum suction. This technique is appropriate for 
blockages containing blood clots. 
 
Fig. 4 Directional Atherectomy 
[http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/05/devices.htm] 
 
 
Fig. 5 Rotational Atherectomy 
[http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/05/devices.htm] 
 
 
Fig. 6 Transluminal Extraction Catheter 
[http://biomed.brown.edu/Courses/BI108/BI108_2005_Groups/05/devices.htm] 
 
Laser angioplasty 
Laser angioplasty utilizes laser energy to remove atheroma or thrombus as 
opposed to compressing or fracturing the plaque[4]. Laser energy is absorbed by tissue 
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and converted to heat which results in (protein) coagulation and/or vaporization leading 
to membrane rupture and crack formation (Fig.7). Laser angioplasty decreases incidence 
of restenosis by removing part of lesion or leaving a smoother luminal surface[4]. Laser 
angioplasty has the advantage of minimal damage to surrounding tissue. It can be used in 
conjunction or as an alternative to conventional balloon angioplasty[4]. 
 
Fig. 7 Laser Angioplasty 
[http://www.edaya.com/About_Us/Qualifications/Experience/la_cath.htm] 
 
Vascular grafting 
Bypass graft is a surgical procedure of revascularization used to restore and 
improve blood flow to downstream tissue and organ.  Most often seen case is the 
coronary artery bypass graft (Fig.8)[3, 4]. Coronary arterial disease occurs when the 
blood vessel is blocked due to buildup of plaque inside the vessel lumen. Severe blockade 
may cause chest pain (angina pectoris), shortness of breath, and, in some cases, even 
heart attack. A healthy artery or vein graft is used to bypass blood flow from occluded 
coronary artery to improve blood supply to cardiac muscles. Recovery may take 6 to 12 
weeks or more[4]. 
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Fig. 8 Coronary Artery Bypass Graft (CABG) [3] 
 
1.2 Vascular Grafts 
1.2.1 Synthetic Grafts 
In 1952, Voorhees, Jarreski and Blakemore presented the first published 
hypothesis on synthetic tubes as replacements for natural blood vessel deficits [10]. Two 
years later, a porous textile graft made from the nylon derivative Vinyon-N was 
successfully implanted in humans [11]. The field of prosthetic vascular grafts has since 
achieved enormous clinical and laboratory importance. The only textile materials thus far 
that have proved to function satisfactorily are Dacron and Teflon, neither of which loses 
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significant tensile strength even after many years of implantation. Dacron and ePTFE 
have been successfully applied in large diameter blood vessel prosthesis [12]; however, 
for small diameter (inner diameter < 6mm) blood vessel replacement, both performed 
poorly in small diameter indications.  
 
Fig. 9 Dacron Vascular Graft: Atrium Ultramax™ Knitted Velour Dacron®  
[http://www.atriummed.com/Common/Images/ultramax-inset.jpg] 
 
 
1.2.2 Biological Vascular Grafts 
Biological vascular grafts are generally inductive to host cell repopulation, and 
may have similar mechanical properties to that of native arteries. Based on the source of 
vascular grafts, it could be categorized into autologous grafts (self tissues), allografts 
(donated from other individual) and xenografts (animal tissues).  
Common autologous grafts are derived from saphenous vein or internal mammary 
arteries [13, 14]. Autologous grafts have several advantages. First of all, compared to 
allografts and xenografts, they do not provoke immune rejections since they are host 
tissue from other parts of the body. Secondly, they are non-thrombogenic; because 
endothelialized vessel lumen provides hemacompatible environment. Up to present day, 
although artificial vascular grafts made of synthetic materials have been successful in 
large diameter applications, autologous grafts are still the gold standard for small 
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diameter vascular graft applications [14-16]. They are superior to synthetic material made 
graft for having better patency rate. However, autologous grafts are not always available. 
The quantity is limited; autologous vessel is not available in about 1/3 of the patients [17, 
18]. Some patients may need reparative surgeries and thus there may not be enough 
vessels to harvest. Moreover, for patients having some vascular diseases or diabetes, 
autologous blood vessels may have pathologic conditions and may not be suitable for 
transplantation. 
Allografts may be more available than autologous grafts; however, they have 
problems of immune rejections and risk of possible disease transfer. On the market, 
CyroLife, Inc. is the first biomedical company which commercially develops low 
temperature preservation of implantable human tissues for cardiac and vascular surgical 
reconstruction. SynerGraft® is CryoLife’s patented decellularized technology that reduces 
the presence of allogenic donor cells associated with biological tissues, while maintaining 
the structural integrity of the underlying collagen matrix. Clinical applications indicated 
that the decellularization reduced immunogenicity [19-23], but in some cases, 
decellularized vein allografts, when used in arterial grafting, led to aneurysmal 
degeneration [20, 24-26].    
Another biological source is xenografts harvested from animals like pigs or cows. 
The most apparent advantage of this source is abundant supply. However, it has the same 
problems as allograft does. More intense immune rejections and risk of possible cross-
species diseases (such as porcine endogenous retrovirus in the case of pig-to-human 
transplantation[27]) transfer hinders the direct use of xenografts in human. The alpha-gal 
 epitope (Galα1-3Galβ1-(3)4GlcNAc
glycoproteins of non-primate mammals by the 
galactosyltransferase (alpha
approximately 1% of circulating immunoglobulins
immunological barrier, preventing the transplantation of pig organs into humans.
circumvent this pitfall such as immunogenicity, a proper decellularization processing is 
required. In addition, a crosslinking reagent like glutaraldehyde is used to crosslink ECM 
protein to stabilize the graft and reduce immunogenicity as well 
 
Fig. 10 α-Gal Epitope (Gal
structure abundantly synthesized in non
barrier of xenotransplatation.
 
1.3 Overview of Vascular
1.3.1 The Need for Vascular Tissue Engineering
Vascular diseases pose great threat to human health. 
pharmacologic drug therapy available
11
-R) is abundantly synthesized on glycolipids and 
glycosylation enzyme alpha1, 3
 1, 3GT). Humans produce the anti-Gal antibody, constituting
[28]. Anti-Gal has functioned as an 
[29, 30]
[http://plaza.snu.ac.kr/~byungkim/images/29.gif] 
α1-3Galβ1-4GlcNAc-R). α-Gal is a common carbohydrate 
-primate mammals, and it is the major 
 
 Tissue Engineering 
 
In most cases, 
; diseased or damaged blood vessels need 
 
 
 To 
.   
 
there is no 
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replacement by surgery in the long run. The clinical demand for vascular biomaterials in 
the form of tubular grafts and patches is considerable.  
Many of these synthetic materials and devices restore the required function, 
increase quality of life significantly and exhibit satisfactory mid-term performance. 
However, on the long term, these non-living materials fail to fully integrate into the 
biological and mechanical milieu to which they are subjected. [31-33]. Lack of growth 
potential, and long term results have revealed several material-related failures, such as 
stenosis, thromboembolization, calcium deposition and infection [34]. Other problems 
like compliance mismatch[35-37], susceptibility to infection[12, 38-40], lacking of 
remodeling potential[34, 41], poor elasticity[42] have also been noticed. Taking vascular 
access in hemodialysis patients as example,  synthetic material ePTFE arteriovenous 
grafts are associated with complication rates that are close to three times higher than rates 
with vein fistulae [15]. Even worse performance in coronary or below-knee bypasses than 
in hemodialysis access precludes synthetics from widespread clinical use.  
Small diameter grafts (inner diameter < 6mm) are highly needed for coronary 
bypass and carotid surgeries and replacement of other peripheral arteries. Until today, 
autologous grafts based on saphenous veins or mammary arteries are still the golden 
standard. Autologous vessels, however, are not available in about 1/3 of the patients 
because of trauma, vessel disease or previous harvest [18, 43]. The invasive harvest 
process may cause considerable donor site morbidity. Small diameter synthetic vascular 
grafts tend to fail either by acute thrombosis or neointimal formation in the long run 
leading to occlusion of blood vessel. By five years, up to 60% of synthetic grafts will 
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occlude or require revision compared with 20% to 30% of vein grafts [44]. Low flow 
shear rate in small diameter vessels favors platelet deposition and thrombus formation, 
which can severely compromise the long term patency of vascular implants [45]. 
The ideal vascular graft should be biocompatible and have mechanical properties 
that approximate native tissue. The blood contacting surface should not be thrombogenic. 
Adequate mechanical properties [46-51] include sufficient burst strength, similar 
viscoelasticity and compliance that match that of native arteries.  
Tissue engineering holds great potential in fulfilling the need for ideal vascular 
grafts. By combining living cells and proper scaffolds, tissue-engineered grafts could 
grow, remodel and would be capable of integrating with host body in the long run. 
 
1.3.2 Approaches in Vascular Tissue Engineering 
Tissue engineering, according to the definition given by Dr. Langer and Dr. 
Vacanti in Science 1993, is “an interdisciplinary field that applies the principles of 
engineering and life sciences toward the development of biological substitutes that 
restore, maintain, or improve tissue function or a whole organ” [52]. Typical tissue 
engineering approaches employ scaffolds and cells brought together in such a way as to 
restore function and facilitate regeneration of the replaced tissue. Several methods have 
been reported, including a completely cellular approach [45, 53], use of decellularized 
tissues [54-56], and combinations of cells with natural or synthetic scaffolds [47, 57], 
including promising biodegradable elastomeric polymers [52, 58, 59].  
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With few exceptions, tissue engineering approaches have relied on scaffolds to 
provide biological and mechanical support for cells. To achieve clinical success, vascular 
scaffolds should exhibit adequate porosity[60] and controlled biodegradability[61], be 
fully cytocompatible[61] and capable of being repopulated and remodeled by host cells, 
and express lack of antigenic determinants[62] and low thrombogenicity[63]. Mechanical 
strength, deformability, elasticity, and compliance are essential to withstand circulatory 
pressures immediately after implantation to prevent early failure, as well as at later 
stages, during tissue remodeling [64, 65]. Overall, this appears to be an “all or nothing” 
scenario (unless all of these requisites is fulfilled, imperfect scaffolds may be in no way 
suitable for clinical use). 
The cells used to seed the developing tissues should be nonimmunogenic, highly 
proliferative, easy to harvest and have the ability to differentiate into application-specific 
cell types with specialized functions[66]. Autologus cells could be harvested from a 
section of host blood vessels. However, there is limited availability of blood vessel and 
the pain accompanied with the invasive procedure may hinder the applicability. Stem 
cells and progenitor cells holds great potential in the application of tissue engineering. 
These cells could differentiate into many cell types, including vascular cells.  Adult stem 
cells have been found in several tissue types such as bone marrow and peripheral 
blood[67], skeletal muscle[68] and adipose tissue[69]. In 2003, Matsumura et al reported 
that bone marrow cells seeded on biodegradable scaffolds expressed endothelial cell 
lineage markers, such as CD34, CD31, Flk-1, and Tie-2, then expressed endothelial cells 
markers, such as CD146, factor VIII, and CD31, and smooth muscle cell markers, such as 
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alpha-smooth muscle cell actin, SMemb, SM1, and SM2 in eight weeks of implantation 
in the inferior vena cava of dogs [70].  
Cell seeded constructs need to be cultured in vitro for a period of time for 
maturation. A bioreactor is served to provide adequate nutrient and waste transport to 
support cell/tissue growth; moreover, simulate the physiological environment in which 
the tissue grows so to better “condition” the tissue construct for implantation. Bioreactor 
conditioning would affect cell viability, cell proliferation, ECM content in the tissue 
construct. It has been shown that dynamic mechanical conditioning dramatically 
improved the mechanical properties of tissue-engineered blood vessels [71]. 
 
1.3.3 Current Status of Tissue-Engineered Vascular Grafts 
In 1986, Weinberg and Bell [72] successfully created the first tissue-engineered 
grafts using collagen gels and cultured bovine endothelial cells, smooth muscle cells and 
fibroblasts on the collagen-based scaffolds; however, the mechanical strength did not 
meet the requirements. Dacron meshes were needed to enforce the tubular collagen 
scaffold. The lack of enough burst pressure prevented its application. Campell et al 
[73]created an “autologus artificial tubular conduit” by inserting a silicone mandril into 
the peritoneal cavity of rats or rabbits. Two weeks later, several layers of myofibroblasts, 
collagen matrix, and a single layer of mesothelium covered the mandril. After removal of 
the silicone mandril, the tube of living tissue was everted, and the tubular structure now 
had an inner lining of nonthrombotic mesothelial cells, a "media" of smooth muscle–like 
cells, collagen, and elastin, and with an outer collagenous "adventitia." The tube of tissue 
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(10 to 20 mm long) was successfully grafted by end-to-end anastomoses into the severed 
carotid artery or abdominal aorta of the same animal in which they were grown[73]. 
L’Heureux et al developed a tissue-engineered blood vessel based exclusively on the use 
of cultured human cells. Cohesive cellular sheets were produced by culturing human 
smooth muscle cells, fibroblasts with the addition of ascorbic acid. Layers of collagenous 
sheets were stacked and wrap around a tubular support to make a tubular conduit. After 
maturation, endothelial cells were seeded in the lumen [15, 45, 55]. In 2001, Shin’oka et 
al implanted a tissue-engineered pulmonary artery into a three-year-old patient. Tubular 
scaffold composed of a biodegradable polycaprolactone–polylactic acid copolymer was 
reinforced with woven polyglycolic acid and seeded with autologus cells harvested from 
peripheral veins. The graft was transplanted ten days after seeding. No evidence of graft 
occlusion or aneurysmal changes on chest radiography seven months post 
transplantation[74]. 
 
1.4 Decellularized  Tissue Scaffolds 
Scaffolds composed of purified or reconstituted extracellular matrix (ECM) 
proteins and decellularized tissues have been widely used in tissue engineering. 
Advantages of using animal tissues to make scaffolds include: abundant supply, 
constituent ECM proteins are supportive of cells growth, tissues have similar anatomical 
structures to that of human’s. 
To reduce immunogenicity, xenogenic and allergenic cellular antigens must be 
removed so that the implant will not incite inflammatory response and immune-related 
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rejection of tissue. For example, porcine tissue has been known to carry alpha-gal 
epitope. Human anti-Gal antibody binds to the alpha-gal epitopes expressed on pig cells 
thus preventing the direct xenotransplatation from pigs. The recent generation of 
knockout pigs that lack alpha-gal epitopes has resulted in the elimination of this 
immunological barrier[28, 75, 76] ( Although Gal is a dominant determinant of xenograft 
immunogenicity, it is clearly not the only one[27]). Decellularized blood vessel may 
retain its ECM components and mechanical strength which makes it ideal for vascular 
graft.  
The goal of decellularization is to efficiently remove all cellular and nuclear 
material while minimizing any adverse effect on the composition, biological activity and 
mechanical integrity of the remaining ECM [77]. Common decellularization protocols 
usually combine physical and chemical treatments. There is no universal decellularization 
protocol. The efficiency of cell removal is dependent on the specific tissue and 
decellularization methods used. Incomplete removal of cellular component may still 
incite immune response; moreover, it has been reported that cellular remnants may be 
responsible for calcification [78-81].  
 
1.4.1 Detergent-based Decellularization 
Ionic detergents are effective for dissolving cytoplasmic and nuclear cellular 
membranes. The most common ionic detergents are the sodium dodecyl sulfate (SDS) 
and sodium deoxycholate and Triton X-200 [82-88]. SDS is effective in decellularization, 
however, it tends to disrupt the native tissue structure and denature protein as in SDS-
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PAGE (polyacrylamide gel electrophoresis). SDS disassociates native protein structure to 
individual polypeptides.  Many researchers have reported destabilized collagen structure 
and decrease in GAG content after SDS treatment. Sodium deoxycholate is also very 
effective for removing cellular remnants, but tends to cause greater disruption to native 
tissue than SDS does [77]. Detergent residue in tissue has always been an issue. It may 
retard later host cell repopulation; cytotoxic effect of residual detergents have been 
reported, leading to lysis of host cells, less efficient in repopulation and prevention of 
ECM remodeling [89]. Adequate rinsing is required.  
When compared to ionic detergents, non-ionic detergents are milder, less 
disruptive on tissue structure. Non-ionic detergents disrupt lipid-lipid and lipid-protein 
interactions, but leave protein-protein interactions intact so that proteins within a tissue or 
organ following non-ionic detergent treatment should be left in a functional conformation 
[90]. Triton X-100 is the representative of this category. When acting on cells, Triton X-
100 does not lyze the cell membrane, instead, it creates holes on the membrane resulting 
in release of cellular components. For the impact on ECM, Triton X-100 led to a nearly a 
complete loss of GAGs and decreases in the laminin and fibronectin content of the valve 
tissue [91].  It was found that treatment with Triton X-100 severely altered  tendons with 
respect to the tensile strength of collagen fibers isolated from the tendon [77]. The 
effectiveness of Triton X-100 has mixed results. Some studies showed that Triton X-100 
was not effective in complete removal of cellular materials from a blood vessel, tendon, 
and ligament after exposure for up to 4 days [49, 83, 92]. However, we should bear in 
 19
mind that the efficacy of any specific reagent is dependent upon the tissue being 
decellularized and other methods with which it is combined.  
 
1.4.2 Alkaline and Acid Treatments 
Alkaline and acid treatments are used to solubilize the cytoplasmic components as 
well as remove nucleic acids. Acetic acid, peracetic acid, hydrochloric acid, sulfuric acid, 
and ammonium hydroxide can effectively disrupt cell membranes and intracellular 
organelles [93-97]. Alkaline treatment may result in dissociation of important molecules 
such as GAGs from collagenous tissues. 
 
1.4.3 Freezing and Thawing cycles[98-104] 
Intracellular ice crystals formed during the freezing process disrupts cell 
membrane resulting in cell lysis, releasing of cellular contents. This method, however, 
may have negative effects of disrupting ECM as well.  The rate of temperature drop must 
be carefully controlled. Following cell lysis, rinsing as well as agitation is needed to 
ensure effective removal of cellular components.  
 
1.4.4 Ultra High Pressure[88, 93] 
Cells can be lysed by applying direct pressure to tissue. Mechanical force can also 
be used to delaminate layers of tissue from organs that are characterized by natural planes 
of dissection such as the small intestine and the urinary bladder[77]. However, high 
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intensity of mechanical forces may damage the ECM leading to the loss the integrity of 
tissue structure. 
 
1.4.5 Enzymatic Methods 
Protease and nuclease are common enzymatic decellularization components. 
Trypsin cleaves the peptide bonds on the carbon side of arginine and lysine next to non-
proline residues [105]. Nucleases like DNase or RNase are used to digest DNA or RNA 
released from cell lysis.  Prolonged enzymatic digestion with proteases may have 
negative impact on the structure and composition of the ECM. 
 
1.4.6 Other Decellularization Techniques  
Hypertonic and hypotonic treatments are to induce osmotic shock lyses cells but 
this alone does not lead to complete decellularization. Additional enzymatic or chemical 
treatments are usually necessary to remove the cellular debris. Chelating agents such as 
EDTA or EGTA capture divalent cations Ca+2, Mg+2 which are necessary for cell 
attachment to collagen and fibronectin at the RGD sequence. Seizure of these divalent 
cations facilitates removal of the cell from adhering to ECM. EDTA is usually combined 
with trypsin treatment.  
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CHAPTER TWO 
PROJECT RATIONALE 
 
2.1 Introduction 
Collagen and elastin are the most abundant ECM proteins in the vasculature. 
Collagen has been broadly applied in making TE scaffolds, while elastin has found 
limited applications [106, 107].  Even though the biochemical composition of scaffolds 
resembles that of natural tissues, collagen scaffolds display very poor elasticity [64, 108, 
109], which is critical in arterial graft applications. 
Elastin fibers are extracellular matrix proteins that endow vascular tissues with 
resilience, permitting long-range deformability and passive recoil without energy input 
[110]. These properties are critical to the function of arteries, which undergo cyclical 
extension and recoil. The high percentage of constituting hydrophobic amino acids 
residues and intra-crosslinking make elastin a highly hydrophobic and insoluble protein. 
Moreover, elastin is a key molecular determinant of arterial morphogenesis, stabilizing 
arterial structure by regulating proliferation and organization of vascular smooth muscle 
cells [111]. Mature elastic fibers rarely undergo remodeling [112]. Due to its enhanced 
stability and very low turnover, once degraded, de novo elastin formation is quite 
difficult to achieve and unless elastin is stabilized, degeneration and calcification may 
occur upon implantation [113].  
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[Essential Cell Biology, Second Edition, 2004, Garland Science] 
Fig.11 Elastic Fiber. Elastin polypeptide chains are cross-linked together to form 
rubberlike, elastic fibers.  
 
 
Penta-galloyl glucose (PGG) is a derivative of tannic acid, a naturally derived 
polyphenol present in a wide variety of plants. Polyphenols have a hydrophobic internal 
core and numerous external hydroxyl groups. By virtue of this structure, they react with 
proteins, specifically binding to hydrophobic regions but also establishing numerous 
hydrogen bonds, showing particularly high affinity for proline-rich proteins such as 
collagen and elastin [114]. In addition, they are efficient antibacterial agents and reduce 
inflammation and antigenicity  
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Fig. 12 Molecular Structure of Penta-Galloyl Glucose (PGG) 
 
2.2 Hypothesis and Specific Aims 
It is our hypothesis that stabilization of elastin-rich acellular vascular scaffolds 
against the action of elastases would significantly improve their performance as vascular 
grafts. For this purpose, we are proposing to employ the unique properties of phenolic 
tannins as elastin stabilizers. 
Our aims are:  
1) Preparation of biological scaffold which is bioactive and resistant to enzymatic 
degradation, then evaluate constructs in vitro and in vivo 
2) Develop a way of efficiently endothelialize luminal surface of graft 
3) Build a pulsatile bioreactor to test endothelial cell retention under flow 
conditions 
4) In vivo evaluation of constructs using animal models. 
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2.3 Clinical Significance 
Cardiovascular diseases greatly affect people in the working force; when 
cardiovascular diseases strike, it often severely limits the income and savings of affected 
individuals and their families[1].  The following huge expenses of medical treatment 
further impact on economics of the individual and society as a whole. According to 
statistics from AHA, the estimated direct and indirect cost of CVD in the United States 
for 2008 is $448.5 billion[2]. There is huge demand for vascular grafts to be used as by-
pass shunts for myocardial and limb revascularization and as fistulae for dialysis 
access[115]. Artificial blood vessels made of synthetic materials have been successful in 
large-diameter replacements, but they fail when used in small-diameter applications (<5–
6mm) because of poor patency and early graft occlusion [116-118]. In the United States, 
more than 1 million vascular procedures are performed each year involving small-
diameter vessels[119].   
The current criterion standard for bypass grafts is autologous veins or arteries, but 
healthy autograft tissue is not always available, and allografts are in high demand but 
short supply. Limited availability of human grafts combined with inadequate 
performance of small-diameter synthetic grafts make existing alternatives suboptimal 
[119-121]. The fabrication of tissue-engineered vascular grafts appears to hold great 
promise as alternative conduits.  
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CHAPTER THREE 
PREPARATION AND CHARACTERIZATION OF ACELLULAR VASCULAR 
SCAFFOLDS 
 
3.1 Introduction 
Tissue-engineered vascular grafts require elastic, acellular porous scaffolds with 
controlled biodegradability and properties matching those of natural arteries. Elastin 
would be a desirable component for such applications, but elastin does not easily 
regenerate experimentally. Our approach is to develop tubular elastin scaffolds using 
decellularization of porcine carotid arteries (~5 mm diameter) using alkaline extraction. 
Because elastin is susceptible to rapid degeneration after implantation, scaffolds were 
further treated with penta-galloyl glucose (PGG), an established polyphenolic elastin-
stabilizing agent. Scaffolds were compared in vitro with detergent-decellularized arteries 
for structure, composition, and resistance to degradation, mechanical properties, and 
cytotoxicity and in vivo for cell infiltration and remodeling potential. 
Regarding the choice of starting materials of scaffold preparation, it depends on 
the clinical application. For example, arterial grafting requires elastic scaffold; dialysis 
arterial/venous shunt grafting requires a mechanically strong scaffold which could 
withstand to multiple times of puncture. Graft diameter match to native blood vessel is 
also very important. These are all key factors needed to be taken into consideration in 
scaffold choice.  
 
3.2 Materials and Methods 
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3.2.1 Tissue Harvesting 
Fresh porcine carotid arteries of adult pigs were ordered from Animal 
Technologies (Tyler, Texas) and shipped overnight on wet ice. Fresh tissues were soaked 
in phosphate buffer saline (PBS) from the harvesting process. Upon arrival, fresh tissues 
were rinsed with new, cold saline solution and cleaned right away on ice. Adherent fatty 
and collangenous tissues were cut off from carotid arteries, moreover, bifurcations and 
vasa vasorum were carefully inspected, leaving a section of about 5 cm long tubular 
conduits intact for later decellularization. 
 
3.2.2 Decellularization of Porcine Carotid Arteries 
Cleaned porcine carotid arteries were decellularized by soaking in 0.1M sodium 
hydroxide solution at 37°C in water bath for 24 hours. After completion of 24 hours 
decellularization, carotid arteries were rinsed with deionized water extensively to get rid 
of alkaline residue within the tissue. The rising process was repeated for more than 10 
rounds until pH value of the soaking solution dropped to neutral range (pH value below 
8). Prepared tissues were stored in PBS solution in fridge for later use. This sodium 
hydroxide treatment removes all cells and most of the collagen, leaving vascular elastin 
intact (referred to as “elastin scaffolds”). The second method employed 24 h of hypotonic 
shock; extraction with 0.25% sodium-deoxycholate, 0.15% Triton X-100, 0.1% 
ethylenediaminetetraacetic acid, and 0.02% sodium azide in 50 mM Tris–hydrochloric 
acid (HCl) buffer (pH 7.8) with mild agitation for 6 days at 22°C; and changes of the 
solution after 3 days. After rinsing with double-distilled water and 70% ethanol to 
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remove detergents, tissues were treated with a deoxyribonuclease/ribonuclease mixture 
(360 mU/mL for each enzyme) at 37°C. This treatment removes all cells but leaves 
vascular collagen and elastin fibers intact. This treatment removes all cells but leaves 
vascular collagen and elastin fibers intact (referred to as “detergent-decellularized 
artery”). 
 
3.2.3 Scaffold Stabilization 
To reduce in vivo biodegradation, decellularized porcine carotid arteries were 
further fixed with a plant-derived polyphenol, penta-galloyl glucose (PGG). Elastin 
scaffolds were treated for 24h at room temperature with 0%, 0.075%, 0.15%, 0.3%, and 
0.6% PGG in 50mM dibasic sodium phosphate buffer in saline with 20% isopropanol, 
pH 5.5. Samples (n=6 per group) were lyophilized; weighed; treated with 10U/mL of 
elastase in 50mM Tris buffer, 1 mM of calcium chloride, and 0.02% sodium azide at 
37°C for 48h; and then rinsed exhaustively and lyophilized to record dry weight after 
elastase. The difference in dry weight was used to calculate percentage mass loss. 
Resistance to elastase was also compared with that of detergent-decellularized arteries. 
PGG has a hydrophobic internal core and numerous external hydroxyl groups. By virtue 
of this structure, they react with proteins, specifically binding to hydrophobic regions but 
also establishing numerous hydrogen bonds, showing particularly high affinity for 
proline-rich proteins such as collagen and elastin [114, 122].  
  
3.2.4 Serum Neutralization of PGG-fixed Scaffolds 
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PGG treatment endows resistance to enzymatic degradation. PGG are generally 
non-cytotoxic, especially when compared to tannic acid.  However, we found that the 
excessive PGG may reduce cell repopulation and proliferation. In order to overcome this 
problem, we tried to find a method to “neutralize” the tissues, render it more cell friendly 
to cell growth. One possible explanation for this might be the strong negative charges of 
the polyphenolic groups of PGG molecule. Cells are slightly negatively charged; hence 
the strong negative charges of PGG molecule may expel cell settlement onto the 
scaffolds.   
Biomaterials tend to be covered by serum proteins immediately after contact with 
blood. We herein came up with an idea of “neutralizing” the cytotoxicity of PGG by 
soaking the PGG-fixed scaffolds in high concentration of serum before cell seeding. 
Briefly, PGG-fixed scaffolds were soaked in filtered (0.22um) mixture of 50% fetal 
bovine serum and 50% DMEM at 37°C in water bath overnight followed by daily PBS 
rinsing to wash any redundant PGG precipitates. After 6 days of PBS rinsing, the 
scaffolds were ready for cell seeding.  
 
3.2.5 Scaffold Characterization  
 For histological evaluation, paraffin-embedded samples were stained with 
hematoxylin and eosin (H&E), Gomori's one-step trichrome, and Verhoeff van Gieson 
(VVG) stain (n = 4 slides per group per stain). Digital pictures were taken of H&E-
stained samples (n = 2 slides per group) at 400 × magnification, and pore sizes between 
 29
intact elastin fibers were measured using AxioVision Release 4.6.3 digital imaging 
software (Carl Zeiss Micro Imaging, Inc., Thornwood, NY). 
To validate decellularization, total genomic DNA was extracted and purified (n = 
3 per group) using a Fibrous Tissue DNeasy Kit (Qiagen, Valencia, CA) following the 
manufacturers' instructions. DNA samples were subjected to agarose and ethidium 
bromide gel electrophoresis alongside pure DNA standards (10 – 100 ug/mL) followed 
by densitometry using Gel-Pro Analysis Software (MediaCybernetics, Silver Spring, 
MD). DNA levels were calculated from the standard curve and normalized to initial 
tissue wet weight. 
Chemotaxis assays were conducted using a Boyden chamber (NeuroProbe, 
Gaithersburg, MD) and a polycarbonate filter with 8-µm diameter pores, as per the 
manufacturer's instructions. Soluble elastin peptides were prepared by treatment of elastin 
scaffolds with ultrapure elastase (10 U/mL in 50 mM Tris buffer, 1 mM calcium chloride, 
0.02% sodium azide) for 24 h. The supernatant was filtered through (Microcon YM-3 
centrifugal devices, Millipore, Billerica, MA) and peptides smaller than 3 kDa were 
collected in the flow-through for chemotaxis assays. Rat aortic fibroblasts and, 
separately, rat aortic smooth muscle cells (1 × 106/well, prepared in house using 
collagenase/explant techniques) suspended in Dulbecco's modified Eagle medium 
(DMEM) and 0.1% bovine serum albumin were used in these tests; undiluted fetal bovine 
serum (FBS; 100%) was used as a positive control, and DMEM and 0.1% bovine serum 
albumin as the negative control. Cells migrated for 4 h at 37°C and 5% carbon dioxide 
(CO2). After incubation, the nonmigrated cells were removed using a wiper blade 
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(NeuroProbe, Gaithersburg, MD) and the filter fixed and stained using a DiffQuik kit 
(Dade Behring Inc, Newark, DE), dried, and screened for migrated cells using an inverted 
microscope. Results were reported as negative (0 – 2 cells per 10 × field), slightly 
positive (2–10 cells per 10 × field), or positive (>10 cells per 10 × field). 
 
3.2.6 Mechanical Properties Testing of Scaffold 
Burst pressures were determined using a peristaltic pump and a piezoelectric 
pressure transducer (Endevco, San Juan, CA) connected to a personal computer through a 
universal serial bus–interfaced data-acquisition module (Omega Engineering Inc., 
Bridgeport, NJ). Tubular scaffolds (n = 6 per group) were measured using digital calipers 
and mounted using plastic ties onto polyethylene connectors, and physiologic saline 
pressure build-up was created by gradually increasing the speed of the peristaltic pump. 
Voltage signal outputs were recorded using LabView (National Instruments Corporation, 
Austin, TX) and transformed into mmHg. Burst pressures were recorded for elastin 
scaffolds and compared with those of fresh carotid arteries and detergent-decellularized 
arteries. 
For compliance testing, a similar setup was used as for burst pressure in which 
tubular scaffolds were subjected to 80 and 120 mmHg using a column of hydrostatic 
pressure, with pressures measured using the transducer and external diameters measured 
using digital photography in six places along the mid-portion of the graft (n = 6 samples 
per group). Compliance was calculated as the difference in diameter increase at the two 
pressures and expressed as a percentage. 
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For tensile testing, samples were cut into 5 × 50 mm dumbbell shapes in the 
longitudinal direction of the blood vessel, and thickness was measured using digital 
calipers and analyzed at a constant uniaxial velocity of 0.1 mm/s until failure using a 10-
Newton load cell on a Synergie 100 testing apparatus (MTS Systems Corporation, Eden 
Prairie, MN). Stress was calculated by dividing the load by tissue cross-sectional area and 
results expressed as stress–strain curves. Elastic modulus (slope at specific strain ± 4 data 
points) was calculated at 20%, 40%, and 60% and at rupture for all samples and results 
compared using analysis of variance (ANOVA) statistical analyses. 
 
3.2.7 Cytotoxicity Test of Scaffolds 
To test for cytotoxicity, 1- cm2 samples cut from 0.3% PGG-treated scaffolds (n = 
3 per stain) were rinsed in phosphate buffered saline for 72 h, incubated overnight in 50% 
FBS in culture medium, and seeded with 30 × 103/cm2 porcine endothelial cells and 
separately with fibroblasts. After 7 days of cell culture and one medium change, cell-
seeded scaffolds were stained with DiffQuik kit (Dade Behring Inc., Newark, DE), 4',6-
diamidino-2-phenylindole, and Live/Dead (Promega, Inc.) stains. 
  
3.3 Results 
3.3.1 Characterization of Elastin Scaffolds 
We used a novel alkali extraction method for preparing elastin scaffolds from 
porcine carotid arteries. Histological analysis confirmed complete decellularization, 
almost complete collagen removal, and presence of spindle-shaped pores averaging 15 to 
 32
30 µm wide and 20 to 70 µm long interspaced between intact elastin fibers (Fig. 13). 
Decellularization was also confirmed according to DNA extraction and agarose gel 
electrophoresis (Fig. 14A), which showed a more than 96% reduction in DNA content. 
Decellularization was not complete with the detergent extraction method, which required 
extensive and repetitive exposure to nucleases for effective cell removal (Fig. 14). The 
alkali extraction method was also shown to result in tubular elastin scaffolds that 
maintained the three-dimensional cylindrical architecture of the artery, easily supporting 
its own weight (Fig. 14B). Furthermore, tubular scaffolds were easy to handle and suture 
to native arteries (ongoing animal implants, data not shown). Smooth muscle cells and 
fibroblasts exhibited strong positive chemotaxis toward peptides obtained from elastase-
treated scaffolds (Fig. 14C–F), suggesting that scaffold degradation would encourage cell 
migration and repopulation of implanted scaffolds. 
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FIG. 13 Characteristics of Acellular Porcine Elastin Scaffolds Derived from Carotid 
Arteries. (A) H&E staining of native arteries showing overall histology. (B) 
Higher magnification showing smooth muscle cells (SMCs) and elastin fibers 
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(ELs). (C) Trichrome stain of native arteries showing overall aspect and (D) at 
higher magnification showing SMCs, ELs, and collagen fibers (COLL, blue). (E) 
Elastin scaffolds showing porous structure by H&E stain, which at higher 
magnification, (F) reveals complete absence of cells and some collagen remnants 
within the inter-fibrillar pores. (G–H) Trichrome staining of the elastin scaffolds 
shows typical elastin fibers (dark red) with some weak collagen staining (blue), 
and absence of cells. 
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FIG. 14 Properties of Elastin Scaffolds: (A) Agarose/ethidium bromide gel 
electrophoresis of whole genomic DNA extracted from fresh carotid arteries 
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(lane 1), detergent-extracted arteries after first (2) and second extraction (3), 
alkali-extracted carotid arteries (4) showing complete lack of DNA and a 
genomic DNA standard (5). (B) Macroscopic aspects of fresh arteries and alkali-
extracted arteries. (C) Chemotaxis of smooth muscle cells and (D) fibroblasts for 
peptides obtained by elastase digestion of alkali-extracted elastin. Black arrows 
are pointing at one of many migrated cells. (E) Positive chemotaxis control, (F) 
Negative chemotaxis control. 
   
3.3.2 Scaffold Stabilization 
To optimize elastin stabilization, tubular vascular elastin scaffolds were treated 
with different PGG concentrations and subjected to elastase digestion (Fig. 15A). 
Untreated elastin scaffolds degraded almost completely in elastase, indicating that the 
scaffold was inherently biodegradable. As PGG concentration increased, there was a 
significant decrease in mass loss, reaching a plateau at approximately 0.3% PGG. Thus, 
we chose treatment of elastin scaffolds with 0.3% PGG. In a second experiment, 
resistance to elastase of the PGG-treated scaffolds was compared with those of detergent-
extracted arteries (Fig. 15B, C). Results showed that detergent-decellularized arteries 
were as degradable as alkali-extracted arteries and that PGG interacts with elastin fibers 
within the scaffold and renders them resistant to enzymatic degradation.  
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FIG. 15 Stabilization of Elastin Scaffolds. (A) Resistance to elastase of penta-galloyl 
glucose (PGG)-treated elastin scaffolds; a concentration study. Percentage mass 
loss after elastase treatment is shown for untreated scaffolds and those treated 
with increasing PGG concentrations. All values were statistically different 
(analysis of variance, p < 0.05). (B) Comparison of resistance to elastase for the 
three main scaffold groups before implantation, untreated elastin scaffolds 
(control), 0.3% PGG-stabilized scaffolds (PGG), and detergent-decellularized 
arteries (detergent). (C) Macroscopic aspect of elastase-treated samples of 
control untreated elastin scaffolds (left) and PGG-treated elastin scaffolds (right). 
(D) Cytotoxicity of scaffolds was tested by seeding endothelial cells (ECs) and 
fibroblasts (Fbs) separately on 0.3% PGG-treated scaffolds (PGG) and untreated 
scaffolds (control). Cells growing on the surfaces were stained with DiffQuick to 
show nuclei and cytoplasm, with 4',6-diamidino-2-phenylindole for nuclear DNA 
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stain (blue fluorescence) and with live/dead stain (live cells stain green and dead 
cells red). All bars are 20 um. 
 
3.3.3 Mechanical Properties of Scaffolds 
In vitro analysis (Fig. 16A) showed burst pressures of fresh carotid arteries at 
approximately 2000 mmHg, values that were not significantly different from those of 
detergent-decellularized arteries (p > 0.05). Vascular elastin scaffolds obtained using 
alkaline extraction exhibited mean burst pressures values of 630 mmHg (p < 0.05 
compared with fresh artery). After PGG treatment, burst pressure values increased to 
more than 800 mmHg, but these values were not statistically different from those for 
untreated elastin scaffolds (p > 0.05). Most elastin scaffolds exhibited similar burst 
patterns, with circumferential ruptures predominating over longitudinal tears (Fig. 16B). 
Vascular elastin scaffolds showed distensibility similar to that of fresh arteries at low 
strains and lower ultimate stress at higher strains (Fig. 16C). PGG fixation changed the 
shape of the curve and showed stiffening of the scaffolds at low strains while maintaining 
similar slopes at higher strain levels. For example, at 20% strain, the elastic moduli were 
0.11 ± 0.01 MPa for control, 0.20 ± 0.02 MPa for 0.15% PGG, and 0.49 ± 0.03 MPa for 
0.3% PGG (all values statistically different, p < 0.05). All samples failed by rupture at 
approximately 1.5 ± 0.7 MPa (p > 0.05), indicating that neither decellularization nor PGG 
fixation influenced overall tissue tensile strength. 
Extensibility testing at 80 and 120 mmHg showed 7.5 ± 2% compliance for fresh 
arteries and 20 ± 4% for elastin scaffolds. However, after PGG treatment, the compliance 
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decreased to almost physiologic levels of 9.5 ± 1% (not statistically different from fresh 
arteries, p > 0.05). 
Taken together, the data show that PGG reduced distensibility and stiffened 
vascular elastin scaffolds, indicating that PGG interacts with elastin fibers within the 
aortic tissue without affecting cytotoxicity. 
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FIG. 16 Mechanical Properties of Elastin Scaffolds. (A) Burst pressures for fresh carotid 
arteries, untreated elastin scaffolds (control), 0.3% PGG-stabilized scaffolds 
(PGG) and detergent-decellularized arteries (detergent). (B) Representative 
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macroscopic pictures showing two patterns observed during burst pressure 
analysis, radial tears (left) and longitudinal tears (right) of elastin scaffolds. (C) 
Representative stress–strain curves for fresh carotid arteries, untreated elastin 
scaffolds (control), and 0.15% and 0.3% PGG-stabilized elastin scaffolds. 
 
3.3.4 Cytotoxicity Test of PGG-stabilized Scaffolds 
Direct-contact cytotoxicity tests showed that alkali-purified elastin scaffolds were 
cell friendly and that PGG treatment did not render the scaffold cytotoxic (Fig. 15D). 
Endothelial cells and fibroblasts attached and spread onto the surface of scaffolds without 
visible signs of cell death. 
 
3.4 Discussion 
Decellularization is an essential step in scaffold preparation for tissue engineering 
because it serves to remove antigenic cellular components. Several approaches have been 
reported in the literature for decellularization, most of which use detergents and enzymes. 
We showed previously that detergent-decellularized arteries have a limited potential for 
repopulation with cells in vitro[123] and in vivo[124]. We hypothesized that the presence 
of the dense collagen–elastin network of fibers is responsible for the lack of experimental 
cell repopulation. To test that hypothesis, we treated decellularized arteries with 
collagenase and improved cell infiltration but also significantly changed mechanical 
properties of the scaffolds[124]. Because elastin regenerates slowly in tissue-engineered 
constructs, our goal was to obtain porous, cell- and collagen-free vascular elastin 
scaffolds from porcine carotid arteries and use them as building blocks for small-diameter 
vascular grafts. We screened several methods for elastin purification and eventually 
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chose to use the NaOH extraction method, which was compared with a traditional 
detergent-based method. Alkaline-extracted carotid arteries showed complete lack of 
cells according to histology and DNA analysis while maintaining elastin and 
proteoglycans intact. The tubular porous scaffolds maintained a cylindrical architecture, 
were capable of supporting their own weight, and were easy to handle and suture. The 
scaffolds were almost completely degraded by elastase in vitro, and their degradation 
products stimulated cell migration in a chemotaxis assay. Mechanical properties of the 
vascular elastin scaffolds, including tensile strength and distensibility, were similar to 
those of fresh arteries, but scaffolds exhibited lower burst pressure values and higher 
compliance, possibly because of loss of tissue collagen. In our experiments, the burst 
pressure of the scaffolds were about 600-800 mmHg. Although this was much lower than 
that of fresh carotid arteries which had a burst pressure of more than 2000 mmHg, this 
might still be good in clinical application. Normal blood pressure fluctuates between 
80/120 mmHg; for some hypertension patients, the high blood pressure may reach as high 
as 180 mmHg. This value is still well below 800 mmHg. Secondly, we believe that after 
implantation, the scaffolds would remodel as time goes by. With host ECM deposition, 
the scaffolds have the potential to grow stronger and finally integrate with host body.   
Biological scaffolds, including those made of collagen and elastin, are prone to 
host enzymatic degradation. To gain control over in vivo degradation rates, we stabilized 
our elastin scaffolds with PGG, a polyphenol derived from plants. Our previous studies 
have demonstrated that polyphenols bind to elastin and in doing so renders it resistant to 
degradation[125]. By virtue of their elastin-binding properties, polyphenols also reduce 
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calcification of glutaraldehyde-fixed bioprosthetic heart valves [113] and limit vascular 
degeneration associated with aneurysm formation and progression [126]. In our current 
studies, we hypothesized that, by delaying host tissue remodeling processes, we would 
help maintain vascular graft mechanical strength and patency for a longer period of time 
and allow for gradual remodeling to occur. PGG stabilized elastin scaffolds in a 
concentration-dependent manner, reduced distensibility, and stiffened vascular elastin 
scaffolds but did not influence overall tensile strength or burst pressure and reduced 
compliance levels to physiologic levels, indicating that PGG-treated elastin scaffolds may 
have adequate properties to be used as vascular arterial grafts. We chose 0.3% PGG as 
the concentration to be used in the experiments as the balance point between cytotoxicity 
and ECM stabilization. 
 
3.5 Conclusions 
Alkaline-extracted carotid arteries showed complete lack of cells according to 
histology and DNA analysis and almost complete collagen removal while maintaining 
elastin and proteoglycans intact. Our novel alkaline decellularization method was 
effective and efficient, resulting in a porous elastin scaffold. The tubular porous scaffolds 
maintained a cylindrical architecture, were capable of supporting their own weight, and 
were easy to handle and suture. Biological scaffolds, including those made of collagen 
and elastin, are prone to host enzymatic degradation. To gain control over in vivo 
degradation rates, we stabilized our elastin scaffolds with PGG, a polyphenol derived 
from plants. PGG-stabilized elastin scaffold also demonstrated good mechanical 
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properties as shown in adequate burst strength, and similar compliance value to that of 
fresh tissue.  
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CHAPTER FOUR 
IN VIVO BIOCOMPATIBILITY TEST OF PGG-STABILIZED ACELLULAR TISSUE 
SCAFFOLDS 
 
4.1 Introduction 
To test biocompatibility of our PGG-fixed elastin scaffolds, small pieces of 
scaffolds were implanted subcutaneously in rats. The incision was closed by staples and 
the rats were kept for either 4 weeks or 8 weeks before sacrifice. Explanted scaffolds 
were characterized by histology, immunohistochemistry and calcium content using 
atomic absorption 
 
4.2 Materials and Methods 
4.2.1 Scaffold Preparation 
Decellularized porcine carotid arteries were prepared by the either alkaline or 
detergent-based method as described in chapter3.2.2. Three sample groups were prepared 
as follows: control untreated elastin scaffold, PGG-treated elastin scaffold (0.3% PGG), 
and detergent-decellularized arteries. Samples were cut into 5× 20 mm shapes and rinsed 
in sterile saline before implantation. 
 
4.2.2 Rat Subdermal Implantation 
Male adult Sprague-Dawley rats (weighing 250 g, Harlan Laboratories, 
Indianapolis, IN) were sedated with acepromazine (0.5 mg/kg, Ayerst Laboratories, 
Rouse Point, NJ) and maintained on 2% isoflurane during surgery. A small transverse 
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incision was made on the backs of the rats, and two subdermal pouches (one superior and 
one inferior to the incision) were created. Samples were implanted into the subdermal 
pouches (n = 6 implants per group per time point) and incisions closed with surgical 
staples. After surgery, the rats were allowed to recover and permitted free access to water 
and food. The Animal Research Committee at Clemson University approved the animal 
protocol, and National Institutes of Health guidelines for the care and use of laboratory 
animals (publication #86-23 Rev. 1996) were observed throughout the experiment. Rats 
were humanely euthanized using CO2 asphyxiation at 4 and 8 weeks after surgery and 
samples retrieved for analysis. A small section of each explant with its associated capsule 
was fixed for histological evaluation. The remainder of the explants were cleaned free of 
capsule using micro-dissection, rinsed in saline, and then divided for analysis. 
 
Fig. 17 Biocompatibility Test using Rat Subcutaneous Implantation Model. Small strips 
of acellular scaffolds were implanted subcutaneously in rats and kept for 4 weeks 
till sacrifice.   
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4.2.3 DNA content 
For DNA analysis, explants (n = 3 per group) were weighed, and total genomic 
DNA was extracted and purified using the Qiagen kit described above. Content of pure 
DNA was measured using ultraviolet spectrophotometry at 260 nm with background 
correction at 320 nm. DNA levels were calculated from a standard curve and expressed 
as ng/mg wet weight. 
 
4.2.4 Histological Studies 
For histology, samples were placed in formalin and paraffin sections (5 µm) were 
stained with H&E, Gomori's one-step trichrome, and VVG (n = 6 slides per group per 
stain). Two independent investigators measured cell infiltration depth on H&E- and 
trichrome-stained slides (n = 3 slides per group per time point) using AxioVision Release 
4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc.). Results were expressed as 
% ± standard error of the mean (SEM) of total scaffold thickness. Cell density in areas 
infiltrated by cells (outside one-third of each section) was measured on H&E-stained 
sections by digitally overlaying a 50 × 50 um grid and counting cell nuclei within the grid 
(n = 10 measurements per group). Results were expressed as cell density (mean number 
of cells/250 um2 area ± SEM). 
 
4.2.5 Immunohistochemistry Studies 
For immunohistochemical identification of infiltrating cell types, sections were 
exposed to 0.1% proteinase K solution (25 U/500 mL, Qiagen DNeasy Tissue Kit) in Tris 
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buffered saline (TBS), pH 7.5 at 22°C for 30 s. Endogenous peroxidases were blocked 
with 0.3% hydrogen peroxide in 0.3% normal sera (Vectastain Elite ABC kit for rabbit 
immunoglobulin (Ig)G, Vector Laboratories, Burlingame, CA). Sections were 
immunostained using mouse anti-rat monoclonal antibodies to alpha-smooth muscle cell 
actin (1:200, Sigma), macrophages (1:200, Chemicon, Temecula, CA), vimentin (1:200 
dilution, Sigma), CD8 (1:200, Sigma), and active prolyl-4-hydroxylase (1:200 dilution, 
Chemicon) at 22°C for 1 h. To minimize cross-reactivity, rat-absorbed biotinylated anti-
mouse IgG was used in place of the biotinylated secondary antibody provided with the 
staining kit. Negative staining controls were performed with the omission of the primary 
antibody. A diaminobenzidine tetrahydrochloride peroxidase substrate kit was used to 
visualize the specific staining (Vector Laboratories), and sections were lightly counter-
stained with hematoxylin. Positively stained cells (dark brown) were counted on each 
section and expressed as percentage of total reactive cells. As positive 
immunohistochemistry controls, we also stained paraffin sections from rat spleen 
(macrophage and lymphocyte control) and rat skin (alpha-smooth muscle cell actin, 
fibroblast and prolyl-4-hydroxylase controls) in parallel with the explant sections. 
   
4.2.6 Phenol Stain 
To visualize phenolic groups, PGG-fixed scaffolds were stained en bloc with 
ferric chloride, embedded in Tissue Tek OCT compound (Sakura Finetek, USA Inc., 
Torrance, CA) and 6- µm-thick sections counterstained with light green. PGG appears 
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brown with this staining [126]. Non-implanted PGG-treated scaffolds were also stained 
for comparison.   
 
4.2.7 Calcification Assay 
For calcification analysis, explanted samples (n = 4 per group per time point) 
were rinsed in saline, lyophilized to obtain dry weight, and individually hydrolyzed in 6 
N HCl, dried under nitrogen, and reconstituted in 1.0 mL of 0.01 N HCl. Calcium content 
was then measured using atomic absorption spectrophotometry as described before[123, 
124, 127]. 
 
4.2.8 MMP Study 
For detection of MMPs in explanted scaffolds, proteins were extracted in 50 mM 
Tris, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 1% sodium deoxycholate, and 150 
mM sodium chloride with protease inhibitor mixture, pH 7.4 buffer, and protein content 
was determined using BCA assay as described before [126] and subjected to gelatin 
zymography using 4 µg of protein per lane alongside molecular weight standards. For 
comparison, extracts prepared from fresh carotid artery, unimplanted elastin scaffolds and 
PGG-treated un-implanted elastin scaffolds were analyzed in parallel with explanted 
samples. MMP-2 and MMP-9 were identified according to their relative molecular 
weights (68–72 kDa and 90–92 kDa, respectively). Intensity of MMP bands (white bands 
on dark background) was evaluated according to densitometry using Gel-Pro Analysis 
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Software (Media Cybernetics, Silver Spring, MD) and expressed as relative density units 
normalized to protein content.  
 
4.2.9 Proteoglycans Quantification 
For quantification of proteoglycans, samples were treated with papain overnight, 
and glycosaminoglycans (GAGs) released into solution were assayed with 1,9-
dimethylmethylene blue reagent using a 0- to 1.25-ug chondroitin sulfate standard curve, 
as described by Hoemann et al[128]. 
 
4.2.10 Hydroxyproline Assay 
Quantification of collagen content, according to the method by Blumernkrantz 
and Hansen[129], was performed to compare the difference between pre-implants and 
explanted tissues. Samples were lyophilized and hydrolyzed in 4N sodium hydroxide 
solution for 2-4 hours to be completely digested, then were neutralized with 1.4N citric 
acid and aliquoted for triplicates. Chloramine T and p-dimetil-amino-benzaldehyde were 
added to digested samples, then vortexed and incubated at 65˚C. At last, 300 ul of 
solution was dispensed into 96-well plate and OD at µ = 550 was recorded. Standard 
curve was made with 6 known concentrations of 0, 10, 20, 30, 40, 50 mg/ml hydroproline 
solution. 
 
4.2.11 Mechanical Properties of Explants 
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In order to compare the difference in mechanical properties between pre-implants 
and explants, small tissue strips were tested for tensile stretch. Elastic modulus was 
calculated and compared at physiological stretch ranges.  
 
4.3 Results 
4.3.1 Histological Study of Explants 
Control untreated elastin scaffolds, PGG-treated elastin scaffolds, and detergent-
decellularized arteries were analyzed at 4 and 8 weeks post-implantation. Histological 
analysis of 4-week explants showed that all scaffolds were generally cell friendly, with 
host cells migrating inward from both sides (adventitia and intima) and repopulating the 
scaffolds gradually (Fig. 18A). An exception was the detergent-decellularized arteries 
group, which showed limited cell infiltration at both time points. Areas of cell infiltration 
coincided with significant degeneration of the elastic fibers (VVG stain, Fig. 18B), which 
were apparently replaced by new collagenous fibers, as evidenced by trichrome stain 
(Fig. 18A). By 8 weeks, extensive inward cell repopulation and remodeling had taken 
place in control untreated elastin scaffolds, as seen by almost complete cell infiltration 
and complete disappearance of the elastin fibers, suggesting that elastin is indeed a 
biodegradable scaffold (Fig. 18C, D). In PGG-treated elastin scaffolds, repopulation and 
elastin degradation had advanced inwards by approximately one-third from each side at 8 
weeks, leaving an intact inner “core” of elastin fibers that was not repopulated or 
remodeled by host cells. The outer areas exhibited well-organized, newly laid down 
collagen fibers, as shown by trichrome stain. VVG stain confirmed these observations, 
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showing less in vivo degeneration of elastin fibers in the PGG-treated samples (Fig. 
18D). These data indicate that alkali-mediated decellularization of arteries is more 
conducive to cell repopulation than detergent-based methods and that PGG treatment of 
vascular elastin has the potential to limit or control scaffold degradation, repopulation, 
and remodeling. These results were confirmed by measurements of DNA content (Fig. 
19A), which correlated with progressively more cell numbers in all groups, fewer cells in 
detergent-decellularized tissues, and intermediate cell numbers in PGG-treated elastin 
scaffolds (all values were different at 8 weeks, p < 0.05).  
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FIG. 18 Histological Analysis of Subdermally Implanted Scaffolds. Representative 
micrographs showing 4-week explants (A and B) and 8 week explants (C and 
D) stained with trichrome stain (A and C) where elastin stains dark red, 
collagen blue and cells pink, and Verhoeff van Gieson stain (B and D), where 
elastin stains black and non-elastin components pink. Samples are shown at 
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lower magnification (micrographs on left of each panel) and higher 
magnification (on right). 
 
4.3.2 Cell Infiltration Depth 
Cell infiltration depth, calculated as the sum of adventitial and intimal depths and 
expressed as percentage of cell-infiltrated distance of total thickness, is shown in Figure 
19B. In all samples, infiltration through the adventitia was almost twice as extensive as 
through the intima (data not shown). Data obtained at 4 weeks of implantation showed 
similar levels in all implant groups (>30% infiltration depth), except in the detergent-
decellularized arteries, which was significantly lower (21 ± 2%, p < 0.05). After 8 weeks 
of implantation, the control untreated elastin scaffold was almost fully infiltrated with 
cells (93 ± 2%), whereas PGG-treated elastin showed significantly less infiltration (72 ± 
2%, p < 0.05). After 8 weeks, the detergent-decellularized arteries showed infiltration 
values similar to those of the 4-week implants (21 ± 2%), indicative of limited potential 
for cell infiltration in these samples. Cell density measured in the infiltrated areas showed 
a similar trend as infiltration depth, namely high density in control untreated elastin 
scaffolds and intermediate cell density in PGG-treated elastin scaffolds (Fig. 19C). 
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FIG. 19 Cell Infiltration and Remodeling Activities in Implanted Scaffolds. Groups 
analyzed were alkali-purified elastin scaffolds (control), 0.3% PGG-stabilized 
elastin scaffolds (PGG), and detergent decellularized scaffolds (detergent) 
before and after 4 weeks (4w) and 8 weeks (8w) of implantation. (A) DNA 
content in explants. Whole genomic DNA was purified from explants and 
quantities expressed as ng/mg wet tissue. (B) Infiltration depth expressed as 
percentage of total scaffold thickness. Insert shows a representative trichrome-
stained section labeled with actual measurements of cell infiltration (full 
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double arrows) through the intima (Int.), adventitia (Adv.), and scaffold 
thickness (dashed double arrow). (C) Cell density measured in infiltrated areas 
expressed as cell numbers/area of 250 um2. Cell density in fresh carotid artery 
is also shown for comparison. (D) Matrix metalloproteinase (MMP) activities 
measured by gelatin zymography and reported as relative density units (RDUs) 
of the white bands normalized to protein content (inset shows representative 
zymogram, with lane numbers corresponding to each RDU bar in the graph). 
MMP-2 and MMP-9 were identified according to their migration distance and 
apparent molecular weights. Unimplanted fresh carotid artery (fresh), alkali-
purified elastin scaffolds (control) and 0.3% PGG-stabilized elastin scaffolds 
(PGG) were also analyzed in parallel with the explants. (E) Content of 
glycosaminoglycans (GAGs) in explants was measured and reported as ug/mg 
of extracted total protein. Unimplanted fresh carotid artery (fresh), alkali-
purified elastin scaffolds (control), and 0.3% PGG-stabilized elastin scaffolds 
(PGG) were also analyzed in parallel with the explants. 
 
4.3.3 MMP and Proteoglycans Assay 
To evaluate potential for remodeling, we analyzed MMP activities in explants and 
compared them with activities in fresh carotid aorta and unimplanted control elastin 
scaffolds (Fig. 19D). Elastin scaffolds exhibited lower MMP levels than fresh tissue, 
indicating that decellularization may remove most protease activities. Practically no 
MMP activity could be detected in PGG-treated scaffolds, indicating that PGG has the 
potential to inhibit MMPs. After 4 weeks of implantation, MMP levels were more than 10 
times greater than unimplanted scaffold levels (Fig. 19D). Conversely, MMP levels were 
approximately 50% lower in PGG-treated scaffolds at 4 weeks. Similar MMP levels were 
obtained after 8 weeks of implantation, indicating that PGG treatment has the potential to 
control MMP activity after scaffold implantation. GAG content analysis showed that 
neither NaOH nor detergent-decellularized arteries had lost any detectable GAGs after 
cell-removal treatments (Fig. 19E, p > 0.2). After 4 and 8 week of implantation, GAG 
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levels had increased significantly in treated and untreated elastin scaffolds, suggesting 
that infiltrating cells had deposited newly synthesized proteoglycans. 
 
4.3.4 Immunohistochemistry  
Immunohistochemical studies showed that infiltrating cells were positive for 
vimentin, alpha-smooth muscle cell actin, and macrophage antibodies and negative for 
cytotoxic lymphocyte antibodies (Fig. 20A). A similar pattern was seen at 8 weeks, 
suggesting that activated fibroblast infiltration could be chronic in these implants and 
could lead to remodeling and regeneration in vascular tissues. As further proof of 
remodeling, a large number of infiltrating cells were also positive for prolyl-4-
hydroxylase, an enzyme actively involved in synthesis of new collagen fibers (Fig. 20B). 
Semi-quantitative analysis of explants obtained at 4 weeks revealed larger numbers of 
macrophages in untreated scaffolds than in PGG-treated scaffolds, whereas at 8 weeks, 
both scaffolds showed similar cell-type distribution (Fig. 20C). 
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FIG. 20 Immunohistochemistry & Phenol Stain of Explants.(A) Immunohistochemical 
staining of cells infiltrating untreated elastin scaffolds (control) and 0.3% PGG 
stabilized elastin scaffolds (PGG) after 4 weeks and 8 weeks implantation. 
Sections were stained with antibodies to rat alpha-smooth muscle cell actin 
(SMActin), macrophages (M-phages), vimentin, cytotoxic lymphocytes (CD8), 
and prolyl-4-hydroxylase (Pro-OHase). Arrows point to one of many positive 
cells (dark brown). CD8 figure lacks arrows because no positive cells could be 
identified. Intima layer is toward the lower-right corner, and scale bars are 20 um 
in all sections. (B) Phenol staining showing elastin-bound PGG (dark brown) in 
PGG-fixed elastin scaffolds before implantation (left) and at 4 and 8 weeks after 
subdermal implantation. (C) Semi-quantitative analysis of cell type distribution 
within implants based on immunohistochemical staining of untreated elastin 
scaffolds (control) and 0.3% PGG-stabilized elastin scaffolds (PGG) after 4 
weeks (4w) and 8 weeks (8w) of implantation. Numbers are expressed as 
percentage of total reactive cells. 
 
4.3.5 Phenol Stain 
Phenol staining of PGG-treated elastin scaffolds showed discrete binding of PGG 
to every elastic fiber, mainly decorating the surface of the fibers (Fig. 15C). This binding 
pattern was well preserved after 4 and 8 weeks of implantation, suggesting that PGG–
elastin bonds are stable for at least 8 weeks in vivo. 
 61
 
4.3.6 Calcium Assay 
Quantification of calcium in explants (Table 1) revealed that untreated elastin 
scaffolds accumulated significant amounts of calcium (>100 ug/mg dry), whereas PGG-
treated elastin did not deposit any detectable calcium salts at 4 weeks (1.4 ug/mg dry) and 
little at 8 weeks (4.4 ug/mg dry), suggesting that calcification may not be a major concern 
in PGG-stabilized elastin scaffolds implanted as vascular grafts. Finally, detergent-
decellularized arteries did not accumulate any significant calcium in our system. 
Calcium content (µg/mg dry weight±standard error of the mean) 
Sample 4 weeks 8 weeks 
Control 103.27±12.17a 117.66±12.01b 
PGG-treated 1.39±0.22 4.47±3.49 
Detergent 0.59±0.16b 0.77±0.05b 
 
Table 1 Calcium Levels in Explanted Elastin Scaffolds 
aStatistical significance between time points within each fixation group (p<0.05). 
bStatistical significance between groups at each time point (p <0.05). 
 
4.3.7 Collagen Content Quantification 
We observed neo-collagen formation in Trichrome staining and 
immunohistochemistry staining of 4-prolyl-hydroxylase. Based on this, we further tried 
to quantify how much neo-collagen was formed during the implantation. Pre-implants 
and explanted tissue were analyzed using hydroxyproline assay. The results showed that 
after 4 weeks of subdermal implantation, the average collagen content decreased. And 
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there was no statistical difference in non-fixed and PGG-fixed explants. During the 4 
week period of subdermal implantation, there were possibly old collagen biodegradation 
and neo-collagen formation at the same time, making it difficult to quantify how much 
neo-collagen was produced. 
 
FIG. 21 Average Collagen Content of Pre-implants and Explants.     
Decellularized porcine carotid arteries strips, either 0.15% PGG-fixed or non-
fixed samples, were implanted subdermally in rat for 4 weeks and retrieved for 
collagen content assay. Bar graph was expressed in mean±SEM. 
 
4.3.8 Elastic Modulus Comparison before and after Implantation 
We calculated elastic modulus of pre-implants and explanted tissues at 10%, 15% 
and 20% strain (Table 2). There is no statistical difference between non-fixed and 0.15% 
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PGG-fixed tissues (both pre-implants), this shows that 0.15% PGG fixation does not 
significantly change the tensile property of decellularized carotid artery (α=0.05). As for 
the explanted tissues (4 weeks of implantation), non-fixed samples had statistically higher 
moduli, this might be due to the fibrous capsule around the implanted samples. These 
surrounding collagenous capsules infiltrated and integrated with the implanted samples, 
and it was almost impossible to define the boundary between the capsule and implants. 
Thus, we observed much higher moduli in these non-fixed samples. As for 0.15% PGG-
fixed implants, the elastic modulus was comparable to that of 0.15% PGG-fixed pre-
implants, suggesting that PGG preserves mechanical properties of scaffolds after 
implantion. 
Table 2 Elastic Moduli of Tissues Pre- and Post-implantation (mean±std) 
 At 10% strain At 15% strain At 20% strain 
Pre-implant, non-
fixed 
1.10±0.25 1.17±0.30 1.28±0.35 
Pre-implant, 
0.15% PGG fixed 
0.82±0.14 0.92±0.16 1.00±0.20 
Explant, non-fixed 15.57±5.01a 11.36±4.21b N/A 
Explant, 0.15% 
PGG fixed 
1.17±0.91a 1.46±1.35b N/A 
Superscript a, b indicates statistical difference (p<0.05) 
 
4.4 Discussion 
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Upon subdermal implantation, elastin scaffolds were readily infiltrated by 
activated fibroblasts and macrophages through the adventitia and intima layers but did 
not seem to have elicited significant immune reactions. Cell infiltration was continuous, 
and at 8 weeks, host cells infiltrating the scaffolds at high density populated almost 100% 
of scaffold thickness. Concomitant with cell infiltration, MMP levels rose, and there was 
gradual elastin degradation and deposition of collagen and proteoglycans. Biological 
scaffolds, including those made of collagen and elastin, are prone to host enzymatic 
degradation. To gain control over in vivo degradation rates, we stabilized our elastin 
scaffolds with PGG. In our current studies, we hypothesized that, by delaying host tissue 
remodeling processes, we would help maintain vascular graft mechanical strength and 
patency for a longer period of time and allow for gradual remodeling to occur. PGG 
stabilized elastin scaffolds in a concentration-dependent manner, reduced distensibility, 
and stiffened vascular elastin scaffolds but did not influence overall tensile strength or 
burst pressure and reduced compliance levels to physiologic levels, indicating that PGG-
treated elastin scaffolds may have adequate properties to be used as vascular arterial 
grafts. Host cells infiltrated the PGG-treated elastin scaffolds at a much lower rate than 
untreated scaffolds, indicating that elastin stabilization possibly reduces cell infiltration. 
PGG-treated elastin fibers were found to degrade similarly to untreated fibers, albeit at a 
lower rate, and were replaced by new collagen fibers and higher levels of GAGs. Overall 
remodeling was correlated with MMP activities and presence of active prolyl-4-
hydroxylase, enzymes involved in collagen degradation and synthesis, respectively. 
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Even after 8 weeks, the middle one-third of the PGG-treated implants still 
exhibited intact elastin fibers, whereas the outer two-thirds (corresponding to the intima 
and adventitia) were more collagenous in nature. This novel hybrid laminar structure may 
possess interesting mechanical properties that require further investigation. PGG-treated 
scaffolds did not appear to be cytotoxic in vitro and in vivo, because most host infiltrating 
cells interacted freely with PGG-treated elastin fibers. Apparently cell types did not differ 
between PGG-treated scaffolds and untreated scaffolds and were typically represented by 
activated fibroblasts and macrophages. PGG binding to elastin appeared to be stable over 
the 8-week study, as revealed by phenol stain, indicating that the bonds are stable under 
physiologic conditions, confirming some of our earlier in vivo observations [126]. 
The third group of scaffolds investigated in this study was the detergent-
decellularized arteries prepared using hypotonic shock, detergents, and nucleases that 
removed most cells but left vascular collagen and elastin fibers intact. These scaffolds 
showed similar susceptibility to elastase (when compared with the alkaline-extracted 
arteries), indicating that the decellularization procedure did not induce significant 
alterations in protein structure. Burst pressure of detergent-decellularized tissues was 
similar to those of fresh native arteries, suggesting that decellularization did not influence 
mechanical properties. Upon subdermal implantation, fibroblasts and macrophages 
infiltrated detergent-decellularized arteries, accounting for not more than 20% of total 
thickness (10% from each side of the implant) at 4 weeks, without eliciting any 
detectable immune reactions. Cell infiltration did not progress with time of implantation, 
and cell numbers, density, and infiltration depths remained constant at 8 weeks, clearly 
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showing that the density of the collagen–elastin network of fibers does not encourage cell 
infiltration and repopulation. Moreover, VVG and trichrome staining and GAG analysis 
did not reveal significant matrix remodeling in the implanted samples, which could be 
explained by the lower levels of cell infiltration in this model. 
 Generally, elastin scaffolds degraded more with time, either non-PGG fixed or 
PGG-fixed scaffolds. 8 weeks samples showed more degradation and more cell 
infiltration than 4 weeks counterparts. Host cells infiltrated into scaffolds and remodeled 
the scaffolds gradually as demonstrated by higher number in cell infiltration depth and 
extensive degradation of the existing scaffolds along with neo-collagen formation. As for 
the differences between PGG and non-PGG samples, PGG-fixed elastin scaffolds showed 
better preserved structure than non-PGG fixed scaffolds. Unlike glutaraldehyde (Glut), 
which is of “permanent” fixation, PGG binding to elastin seems to be “reversible”. Host 
cell infiltration and scaffold remodeling activities increased with time; when compared to 
unfixed samples, PGG-fixed scaffolds exhibited a “delayed” repopulation. We think that 
this is advantageous; as mentioned earlier, Glut-fixed scaffolds do not allow much 
remodeling activities, for its cytotoxicity and stable covalent corsslinking. PGG is milder 
in cytotoxicity and the binding to ECM proteins might be weaker or flexible. Remodeling 
potential is very important. Infiltrating host cells would lay down new ECM proteins and 
thus strengthen the overall mechanical properties of vascular graft. Moreover, grafts 
could grow and integrate with host body. This is important for young patients.    
 
4.5 Conclusions 
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Treatment with PGG reduces the rate of elastin biodegradation in vitro and thus 
may allow for control of in vivo biodegradation. Despite elastin stabilization, PGG-
treated elastin encourages inward cell infiltration, elastin degradation, and matrix 
remodeling and inhibits calcification in vivo. These scaffolds are clearly superior to 
detergent-decellularized arteries in terms of cell infiltration and remodeling potential. 
Interactions between PGG and elastin are strong, and thus the beneficial effects of PGG 
could be maintained in the long term.  
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CHAPTER FIVE 
ENDOTHELIAL CELL SEEDING ON LUMINAL SURFACE OF GRAFTS 
 
5.1 Introduction 
Significance of Endothelium  
Natural blood vessels are lined with confluent endothelial cells on the luminal 
surface. This thin layer of blood-contacting endothelium not only serves as a perfect non-
thrombogenic layer but also has important physiological roles in control of blood 
pressure, angiogenesis and inflammation. Although vascular grafts of animal origin may 
have pre-existent endothelium coverage, this non-self cell layer would incite 
immunological rejection if implanted directly into the recipient without decellularization. 
Either decellularized biological vascular grafts or man-made artificial grafts lack a non-
thrombogenic blood contacting surface. Moreover, humans demonstrate limited 
spontaneous endothelialization of prosthetic bypass grafts  [130], only about 0.1 mm 
trans-anastomotic ingrowth per week in contrast to what is seen in animal models [13]. 
As of that, in vitro endothelialization of grafts is often needed in order to attain 
hemacompatibility [131, 132]. Cell seeding procedures, in general, should be fast, 
efficient and non-toxic and not having negative impacts on cell viability [59, 133, 134]. 
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Fig. 22 DiffQuik Stain & Live/Dead Assay of Statically Seeded Endothelial Cells. 
Confluent endothelium coverage on decellularized elastin scaffold (left); 
Live/Dead assay of live endothelial cells (right). This seeding was performed on 
a small strip of decellularized tissue with high concentration of cell suspension 
fluid. 
 
Static Seeding 
 This traditional method utilizes gravitational force induced sedimentation of cell 
suspension fluid onto the surface of scaffold [135-137]. It is simple without the need of 
complicated equipment. However, this method has several limitations[138]. First of all, it 
is time consuming. It may take hours to have cells settle down. Secondly, it is not 
efficient. Cell suspension fluid tends to flow around, leading to loss of cells available for 
sediment onto the surface. Hence, very high cell density of cell suspension fluid is often 
required. Moreover, the seeding uniformity is another concern. In order to have uniform 
cell distribution on the tubular scaffold, the tubular construct must be rotated periodically 
and wait a substantial amount of time for cell sediment. In addition to these limitations 
mentioned above, this method is limited in superficial seeding applications. Lack of 
strong driving force to push cells inward makes it non-applicable for medial layer cell 
seeding (Fig. 22). 
  
Electrical Field  
Charged particles tend to move in electric field. Cell membrane is negatively 
charged; hence theoretically, by applying an external electrical field, cells would move
the electric field [139-142]
temporary positive surface charge. Whe
onto 4 mm inner diameter ePTFE using the electrostatic cell seeding technique, a 
complete nodal area coverage of morphologically mature ECs (73540 cells/cm
obtained in 16 minutes (+1.0 volt applied) with m
effect on EC viability [143]
The electrostatic seeding procedure is superior to the gravitational and hydrostatic 
procedures in terms of the seeding time required, magnitude of EC adhesion, 
retention[143]. 
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In order to achieve efficient cell seeding within the inner structure of scaffold, a 
method which can provide stronger driving force is needed. Traditional cell seeding 
method like sedimentation of cell suspension fluid can only seed the luminal surface.  
Moreover, cells tend to stay where they are if there are no proper biochemical signal 
gradients to guide cellular movement. Vacuum suction [59, 133, 144] has been proposed 
to be an effective way of repopulating cells within porous tubular construct. A syringe 
pump is applied to induce transmural flow through the porous polymer scaffold. Cells get 
trapped within the pores of the scaffold while the liquid passes through. The tubular 
construct also rotates during the vacuum suction to have more uniform distribution along 
the circumferential direction. In summary, this method combines vacuum suction, 
centrifugal force and flow synergistically. When compared to traditional seeding 
techniques, vacuum may provide more potent driving force to have cells move inward. 
Other seeding techniques like electrical field [139-142] and magnetic nanoparticles [138, 
145, 146] were reported to be used in lumen endothelialization only; this might have been 
due to the weak interaction force of the methods itself. 
 
Chemotaxis 
Chemotaxis is another option we will consider for cell seeding. Generally cells 
tend to migrate towards nutrients, growth factors and other chemokines. In our 
preliminary data using modified Boyden chambers we showed that cells will readily 
migrate towards pure fetal bovine serum used as an the chemo-attractive target[147]. 
Serum rich environments will be created on the adventitial side of our grafts and the 
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resulting concentration gradient would encourage radial cell movement form within the 
lumen. 
 
5.2 Materials and Methods 
Dynamic Seeding & Seeding Device 
Our seeding device was designed in collaboration with undergraduate student 
Charlie Lucky Dunn (CLD) from Mechanical Engineering Dept (now medical student).  
The main chamber could accommodate 4 vascular grafts at a time (Fig. 24). Electrical 
field, hydrostatic pressure seeding and chemotaxis could be employed individually or 
simultaneously. Vascular grafts are mounted into the chamber using Luer-lock 
connectors.  
 
Fig. 24 Cell Seeding Device “Seedinator”. The seeding device is comprised of: (1)an 
enclosed chamber with removable lid, (2)an opening in the lid which allows for 
bubbles to escape from the chamber, (3)intricate Luer-lock systems comprised 
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of H-Flow™ Self-Sealing Hemostatic Flow Valves, and (4)openings 
perpendicular to tissue placement . (courtesy of CLD) 
 
The dimension of the main chamber is 137x101x18 mm (LxWxH).  The chamber 
could hold an approximate volume of 110 ml and contain four 5.4 mm diameter openings 
to fit Luer lock fittings.  An o-ring was placed along the outer lining of box to ensure 
close contact between the lid and chamber for an enclosed inner environment. 
An unique flow valve called “H-Flow™ Self-Sealing Hemostatic Flow Valve” 
(ICU Medical Inc.) is used to (a) syringe cell suspension fluid into grafts loaded into the 
main chamber without leakage; and (b) to permit the placement of internal wire 
conductors within the center of each vascular graft without losing any cellular suspension 
fluid. This valve possess a characteristic of allowing fluid flow in one direction – if the 
proper connection is applied – without allowing fluid leakage in the opposite direction.  
 
Electrical Field (Electrostatic) 
Four decellularized porcine carotid artery grafts of about 5 cm long were mounted 
into the chamber. 3 mL of endothelial cell suspension fluid (cell density 120,000 
cells/mL) was infused into each graft by tilting the device to an angle of 90˚, and forcing 
the fluid up the tissue (in order to safely remove air). Internal conductor wires were then 
inserted into the center of each graft along the longitudinal direction. The extension of 
five internal conductor wires was then connected to the negative terminal of power 
supply to induce an equivalent negative charge in each of the five internal conductors. 
The inner lining of chamber wire was laced around with external conductor wire and a 
tail was placed through one of the perpendicular chamber holes. The copper wire was 
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sealed with silicon to prevent fluid leakage from this orifice, and then connected to the 
positive output terminal of power supply. The internal conductor wires were plastic 
coated to prevent oxidation of metal wires.   
Finally the chamber was sealed and filled with cell culture medium. Cell culture 
medium in the chamber served as an electrolyte solution to promote even charge 
distribution throughout the chamber.  After closing every opening and attaching the 
external wire to the positive terminal of the power supply, the assembly was ready for 
testing. The experiment was run at 1 volt for an hour. Grafts were cut off the device and 
stained with DiffQuik and Live/Dead stain to visualize the cells on the luminal surface. 
 Fig. 25 Experimental Setup of 
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cells/mL) was infused into each graft by tilting the device to an angle of 90˚, and forcing 
the fluid up the tissue (in order to safely remove air). After filling up the chamber with 
culture medium, the lid of the chamber was sealed. A reservoir containing cell culture 
medium was positioned 60 cm above the main chamber. A multi-tap manifold then split 
fluid directly from the reservoir into each graft. After opening valves on the manifold, 
each of the four vessels fully experienced 60 cm of hydrostatic pressure exerted by the 
reservoir. The grafts were removed from the chamber one hour later and quickly rinsed 
with DPBS, cut longitudinally to expose the luminal surface of the graft. Grafts were cut 
off the device and stained with DiffQuik to visualize the cells on the luminal surface.   
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Fig. 26 Experimental Setup of Hydrostatic Pressure Seeding (courtesy of CLD) 
 
Chemotaxis 
Four decellularized porcine carotid artery grafts of about 5 cm long were mounted 
into the chamber. 3 mL of endothelial cell suspension fluid (cell density 120,000 
cells/ml) was infused into each graft by tilting the device to an angle of 90˚, and forcing 
the fluid up the tissue (in order to safely remove air). A chemoattractant fluid, which 
consisted of 80% FBS and 20% DMEM filled the inner chamber of seeding device, and 
then the lid of the chamber was sealed. The whole seeding device was incubated into a 
sterile cell incubator maintained at 37˚C and 5% CO2 for one hour. Grafts were cut off 
the device and stained with DiffQuik to visualize the cells on the luminal surface. 
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Fig. 27 Experimental Setup of Chemotaxis (courtesy of CLD) 
 
5.3 Results 
Electrical field seeding of 1 volt for 1 hour showed good cell coverage as shown 
in the DiffQuik staining. Live/Dead viability assay also showed that seeded cells survived 
in one hour of electrical field treatment. The second mechanism, hydrostatic pressure 
seeding also resulted in good, broad cell coverage. Chemotaxis was the least efficient. 
 
Fig. 28 DiffQuik Staining (top) and Live/Dead Assay (bottom) of Electrical Field 
Seeding 
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Fig. 29 DiffQuik Staining of Hydrostatic Pressure Seeding 
 
5.4 Discussion 
We tested three different dynamic seeding mechanisms: electrical field, 
hydrostatic pressure and chemotaxis. Both electric field and hydrostatic pressure seeding 
demonstrated to be effective and efficient in luminal cell seeding. In electrical field 
method, a metal wire inserted inside the tubular scaffold along the longitudinal direction 
serves as cathode to drive negatively charged cells move toward luminal surface. This 
method works well with rigid synthetic material tubular scaffolds, owing to the perfectly 
tubular shape of artificial scaffold. However, for decellularized biological scaffolds, the 
luminal surface of the graft would inevitably make contact to the metal wire because of 
the much more compliant nature of biological tissue. The contact surface would not be 
covered by cells and when there is electric current running, sometimes it just got burned. 
Secondly, the insertion and retrieval of metal wire may accidentally hit or even punch 
vessel lumen and cause damage to seeded graft surface. Moreover, heat and gas 
generated due to electrolysis of water may pose negative effects on cells. We observed 
tissue burning of the contact between metal wire and luminal surface of graft. Secondly, 
 80
elevated oxidative stress might be harmful to live cells. All in all, these make electrical 
field seeding less favorable. 
The second mechanism, hydrostatic pressure seeding, seems to be more 
applicable. The experimental setup is simple. Grafts filled with cell suspension fluid are 
pressurized by fluid column. This driven force in the radial direction helps transport cells 
to the luminal surface of scaffold. In comparison to the previous electrical field method, 
hydrostatic pressure method is simple, easy to set up and has no problems that come 
along with insertion of wire into the tubular scaffold. DiffQuik and immunofluorescence 
staining demonstrated the feasibility of hydrostatic seeding.  
The third mechanism, chemotaxis, seems to be less favorable. Theoretically, cells 
are attracted and migrate toward the concentration gradient, however, chemotaxis method 
results in least efficiency in all three mechanisms. Based on these reasons, we finally 
picked hydrostatic pressure as the method of use. Hydrostatic pressure and electrical field 
seeding were also shown to be superior to chemotaxis method as confirmed by the work 
of undergraduate student Charlie Dunn in our lab.   
We found one hour incubation in cell incubator at 37˚C, 5% CO2 right after 
experiment would result in better cell coverage when compared to that of no extra one 
hour incubation (data not shown). We suppose that, even if cell would migrate toward 
luminal surface owing to the applied external forces, cells still need some time to attach 
firmly to the surface. Thus, this extra one hour of incubation is necessary; this one hour 
incubation would be implemented into our seeding protocol. 
 81
Seeding density is also a critical factor in seeding. In order to have confluent cell 
coverage over the luminal surface, an extra high number of cells are needed. In our 
experiments, there were still some spotty areas not covered by cells. Our seeding density 
was not as high as reported in the literature, and this might be the reason for the non-
confluent cell coverage. Exposure of collagenous layer to blood flow might induce 
thrombosis and lead to occlusion of graft. Although bioreactor pre-conditioning before 
implantation might help cell proliferation, it is desirable to have as many cells as possible 
to start with to assure that grafts to be fully hemacompatible.  
Synergistic seeding by combining all three mechanisms seems to be another 
option of achieving even more efficient seeding. Our seeding device is capable of 
conducting multiple seeding mechanisms simultaneously as shown in the work of Charlie 
Dunn. Electrical field method has comparable results to hydrostatic pressure seeding; 
however, there are problems associated with electrolysis of water during the process. The 
experimental parameters of electrical field seeding may have to be optimized to minimize 
these negative impacts. If we could overcome these problems, synergistic seeding might 
be a more attractive way of endothelial lumen seeding. 
 
5.5 Conclusions 
We successfully built a custom-made seeding device which is capable of seeding 
cells onto luminal surface of vascular grafts with three different mechanisms: electrical 
field, hydrostatic pressure and chemotaxis individually or synergistically. Of all three 
proposed seeding mechanisms, both electrical field and hydrostatic pressure methods 
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showed good cell coverage. Chemotaxis is least efficient and very time consuming with 
least ideal result. Hydrostatic seeding is simple, easy to set up and operate. Thus, we 
would prefer hydrostatic seeding as the method of choice in the following bioreactor 
studies.  
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CHAPTER SIX 
BIOREACTOR STUDIES 
 
6.1 Introduction 
Under physiological conditions, arteries sustain high blood pressure and flow. 
Cells are subjected to continuous biochemical and biomechanical stimuli. Endothelial 
cells and vascular smooth muscle cells respond to environmental mechanical stimuli in 
many ways. Dynamic mechanical conditioning had dramatically improved the 
mechanical properties of tissue-engineered blood vessels [71]. It has been shown that 
10% cyclic strain is beneficial to graft maturation [71]. Upon stimulation, VSMCs 
increase ECM synthesis and result in higher burst pressure value. In addition, cells 
cultured under static conditions may demonstrate different phenotypes and behave 
differently.  Even endothelial cells from different parts of the vasculature, e.g. arterial and 
venous ECs, are not the same kind of endothelial cells[131], this is due to significant 
differences in flow conditions that exist between arteries and veins. In order to mimic the 
correct physiological conditions to which the cells would be exposed, bioreactor 
mechanical conditioning has become essential. To better simulate physiological 
conditions, an ideal vascular bioreactor should provide pulsatile flow with both internal 
and external perfusion[134].  
The next potential problem is the bonding strength of seeded endothelial cells to 
the underlying scaffold. Even though a confluent endothelial layer could be established 
under static culture, tissue construct cultured under static conditions may not be able to 
withstand sudden environmental changes. Under physiological conditions, arteries sustain 
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high blood pressure and flow. Luminal endothelial layer tends to be washed away due to 
high shear flow[134], and thrombosis may arise owing to the exposure of underlying 
substratum. In vitro incrementally increasing pulsatile shear stress (progressive adaptive 
preconditioning) has been shown to enhance EC retention [57, 148-150]. A bioreactor 
which can simulate these biochemical/biomechanical parameters to not only test 
endothelial retention but also serve as an in vitro preconditioning apparatus before being 
implantation in animal model is needed for vascular tissue engineering. 
 
6.2 Materials and Methods 
6.2.1 Clemson Vascular Bioreactor 
The Clemson vascular bioreactor v.1 was designed by PhD student Lee Sierad in 
our lab. The whole bioreactor is composed of media reservoir, reactor chamber capable 
of mounting five grafts at a time, two manifolds for culture medium dispensing, tubing 
and a cartridge pump. Culture medium is driven by cartridge pump and flows into the 
first manifold then splits into five sub-streams, entering each vascular graft in the 
chamber (internal perfusion). The second manifold connecting the other end of vascular 
grafts merges the sub-streams, and the flow fills into the bioreactor (external perfusion), 
finally goes back to the media reservoir. The media reservoir is vented to the inner space 
of incubator by a 0.2 um filter so as to maintain sufficient gas exchange. 
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Fig. 30 Clemson Vascular Graft Bioreactor v.1; (a) overview, (b) inside cell incubator 
 
 6.2.2 Pulsatile Flow Induced by Pinch Valve 
The circulation of culture media is driven by cartridge pump; however the 
resultant flow is not fully pulsatile. To better simulate the physiological flow condition, 
pulsatile flow is needed. This is achieved by adding a pinch valve to the system. When 
there is electric current running through the pinch valve (BioChem Fluidics), valve 
pinches on the tubing and limits the flow, thus pressure rises; valve opens and flow is 
reestablished then pressure drops when current is cut off (normally open type).  To 
control the action of pinch valve, we employ a “555 timer IC” (Texas Instruments) to 
generate pulse waves to feed the pinch valve. 
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Fig. 31 555 Timer IC at Astable Mode 
“555 timer IC” is comprised of over 20 transistors, 2 diodes and 15 resistors on a 
silicon chip installed in an 8-pin mini dual-in-line package (information from the Texas 
Instruments manual).  When the 555 timer IC is running at “astable mode”, it operates as 
an oscillator with continuous stream of rectangular pulse waves having a specified 
frequency. However, 555 timer IC could only generate 200mA max output and this small 
current is incapable of operating the pinch valve, which requires 600mA at least. Thus an 
additional relay device which could sustain high current and serve as switch is needed.  
To be brief, the 555 timer IC regulates the operation of the relay (the switch is on/off 
periodically), and thus the pinch valve closes and opens repeatedly.   
In the original design of Clemson vascular bioreactor, there was only one media 
reservoir; however, the low pressure induced by opening of the pinch valve was near zero 
or even negative values. Thus, a second media reservoir was added to the system so as to 
provide “back pressure”. By adjusting the height of two reservoirs (145/115 cm), we 
achieved the goal of having a periodic pressure fluctuation of 120/80 mmHg in pre-
experimental setting. 
t1 (C charge up time) = 0.693 (R1+R2)*C
t2 (C discharge time) = 0.693*R2*C
f = 1/(t1+t2), f in Hz, R1 & R2 in MΩ, C in µF
Let f = 1 Hz, t1=0.75s,  t2=0.25s, C=1 µF
Then R1= 720 MΩ, R2 = 360 MΩ
t1
t2
 Fig. 32 Configuration of Clemson Vascular Bioreactor
 
Fig. 33 Pulsatile Bioreactor Having 
by positioning two reservoirs at 145/115 cm above vascular bioreactor 
 
6.2.3 Seeding of Vascular Grafts
Tubular elastin scaffolds of about 5
hydroxide decellularization method described in previous chapters; half of the grafts were 
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further stabilized with 0.15% PGG and underwent six days of PBS long wash and finally 
neutralized with 50% fetal bovine serum/DMEM. For seeding, tubular elastin scaffolds 
were first mounted onto the vascular bioreactor with Luer-lock fitting and cable ties. 
Porcine aortic endothelial cells at passage 7 were seeded on eight elastin scaffolds (Four 
grafts 0.15% PGG-fixed, 4 non-PGG-fixed) using hydrostatic pressure mechanism 
described in previous chapter. Briefly, two syringes were connected to the both ends of 
the vascular graft with Luer-lock connection; cell suspension fluid was then injected into 
the graft gradually, while the syringe on the other end provided suction force and thus 
cell suspension fluid moved along until it filled the whole graft. Seeding density was 
0.275 M cell per graft. The pressurized grafts were left in the cell incubator for 2 hours 
for cell attachment onto luminal surface of grafts. 
 Fig. 34 Hydrostatic Pressure
 
6.2.4 Endothelial cells subject to pulsatile flow
Two media reservoirs were placed in the upper incubator (maintained at 37
5% CO2), while the vascular bioreactor chamber sat in 
establish pressure head needed. Culture medium flowed from the reservoir 1, which was 
higher, down to the lower oven; the flow split into 4 sub
entering into 4 individual grafts; the 4 sub
then entered into the inner space of bioreactor chamber to provide external perfusion; the 
culture medium flow finally went up into reservoir 2 (30 cm below than the first 
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 Seeding of Vascular Grafts 
 
the lower oven (37
-streams after the manifold, 
-streams merged at the second manifold and 
˚C and 
˚C) so as to 
 reservoir). To maintain balance of liquid levels o
operating at 120 ml/min constantly transported culture medium from reservoir 2 to 
reservoir 1. Pulsatile flow was induced by a pinch valve positioned right after the second 
manifold with repetitive closing/opening at 1Hz 
circulated in this close system, and 4 seeded vascular grafts (2 PGG
fixed) were subjected to pulsatile flow for 20 hours to test the endothelial retention. 
Another 4 seeded vascular grafts (2 PGG
served as control. 
Fig. 35 Experimental Setup of 
 
6.2.5 Examination of Vascular Scaffolds after Pulsatile Flow
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 Tubular vascular grafts were harvested 
rectangular strips. We stained these rectangular strips either with Live/Dead
viability assay and DiffQuik stain. For Live/Dead assay, we prepared 2uM calcein AM 
and 4uM ethidium homodimer
for 20-40 minutes in the dark; for DiffQuik assay, scaffold strips were first fixed with the 
blue fixative solution and then 15 seconds incubation in solution 1, followed by 10 
seconds incubation in solution 2. After staining/incubat
over onto glass slide, and observed under fluorescent (Live/Dead assay) or light 
microscope.    
 
6.3 Results 
From Live/Dead cell viability assay and DiffQuik staining, we found that seeded 
endothelial cells could withstand to 20 hours of pulsatile flow. Live/Dead assay showed 
that many cells could withstand to pulsatile flow and 
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 Fig. 36 DiffQuik Staining & Live/Dead Assay of Non
DiffQuik stain; (c),(d) Live/Dead assay
  
Fig. 37 DiffQuik Staining & Live/Dead Assay of Non
DiffQuik stain; (c),(d) Live/Dead assay
 
Fig. 38 DiffQuik Staining & Live/Dead Assay of PGG
DiffQuik stain; (c),(d) Live/Dead assay
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 Fig. 39 DiffQuik Staining & Live/Dead Assay of PGG
DiffQuik stain; (c),(d) Live/Dead assay
 
6.4 Discussion 
We successfully built a pulsatile vascular bioreactor with the addition of a pinch 
valve periodically closing/opening at 1Hz. By adjusting the heights of two media 
reservoirs, we achieved pressure fluctuation within physiological range of 120/80 mmHg 
in the pre-experimental simulation; however, in the real experiment, the pressure 
fluctuation within the vascular bioreactor was estimated to be 87/52 mmHg, not as ideal 
as the pre-run. This was due to the limitation of height difference between two incubator
stacked on top of the other.  In order to achieve physiological 120/80 mmHg pressure, the 
heights of two reservoirs needs to be ~ 145/115 cm, respectively, above the vascular 
bioreactor chamber. We could only get 105/75 cm with the two stacked incubators
Secondly, the volumetric flow rate of the system was about 120 ml per minute in total or 
30 ml/min per graft. This value is 
artery which is estimated to be 30
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which is 250-500 mL/min. This small flow is because of the small orifices of current 
Luer-lock fittings, with smallest opening to be 3 mm in diameter. To increase flow rate, 
larger orifices, fittings and tubing are needed.  
Shear stress value was estimated by Hagen-Poiseuille equation, 
 
 =  
4  
 	
 
τ for stress (in dyn/cm2), µ for fluid viscosity (in dyn*s/cm2), Q for flow rate 
(cm3/s), r for inner radius of tube (cm). 
The approximate shear stress value given by the above equation was about 0.2 
dyn/cm2. This value is small when compared to physiological value in human arteries. 
From Hagen-Poiseuille formula, we know that both fluid viscosity and flow rate are 
associated with the value of shear stress. Blood has a viscosity of about 0.035 poise; 
while the viscosity of culture media (89% DMEM, 10% FBS), 0.0085 poise, is much 
smaller (4-fold) than that of blood. Thus, even if the flow rate of the bioreactor system 
was at physiological level, the resultant shear stress would be only a quarter of 
physiological value.  
Although the shear stress value in this pilot run study did not reach physiological 
level, seeded endothelial cells could withstand to 20 hours of pulsatile flow and stayed 
alive. Moreover, we earned several lesson learns in this pilot run study, and this 
experiences are helpful in improvement of future vascular bioreactor. The next generation 
bioreactor shall have bigger orifices and tubing in order to allow for larger flow. 
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Secondly, a much higher seeding density to start with is needed. Thirdly, the heights of 
two reservoirs in the incubator have to be adjusted so that the pressure fluctuation would 
achieve physiological range.  Our current experimental setup could not fit in regular 
incubator; we used two incubators/oven stacked on the other. The two media reservoirs 
were positioned in the upper incubator and the vascular bioreactor chamber was in the 
lower oven, with long tubing connected these two to allow for media circulation. The 
sterility is also a concern: tubing must be connected between the incubator/oven. In the 
future, we would look for a tall incubator which could accommodate all the components 
or just connect a heart valve bioreactor as pressure/flow input. 
 
6.5 Conclusions 
A pulsatile vascular bioreactor was built to test endothelial cell retention under 
pulsatile shear flow. Endothelial cells were seeded onto the luminal surface of tubular 
elastin scaffolds using hydrostatic pressure method. Live/Dead cell viability assay and 
DiffQuik staining showed that seeded endothelial cells could withstand to 20 hours of 
dynamic flow and stayed alive.   
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CHAPTER SEVEN 
ANIMAL CIRCULATION MODEL & ALTERNATIVE SCAFFOLDS 
 
7.1 Introduction 
The final test, before human clinical application, of tissue-engineered vascular 
constructs is the functionality test using an animal circulation model. Animal models are 
used to stimulate human anatomy, physiology, and pathological processes, with 
extrapolation of findings to human medicine[151]. It is also a requirement for regulatory 
approval by Food and Drug Administration[152, 153].Choosing a suitable animal model 
is of paramount importance.  
 Generally speaking, a good animal model must have similar anatomical 
structures and physiological/pathological progression comparable to human [37]. There 
are many factors need to be considered in animal studies, including animal species, 
anastomotic site, caliber and length of prosthesis, and duration of implantation, cost, 
availability, ease of handling during examinations, response to anesthesia and surgery, 
and arterial size and flow at sites of conduit implantation are often used to guide animal 
selection[151]. 
Comparative hematology and hemadynamics of implant locations are two major 
factors to be considered when choosing appropriate animal models. Animal species of 
comparative hematology  are essential when determining the validity of the in vivo 
thrombogenicity assessment of vascular biomaterials[151]. 
Species selection varies from small mammals (mice, rats) to larger mammalian 
species. Sheep [154-157], dog [158-161] and pig [162, 163] are the most common animal 
 97
models used and baboon was also reported [164]. Pigs[165, 166], dogs[167] and 
sheep[168] have been attributed with a coagulation system that is similar to humans. 
Human cardiovascular anatomy and physiology is closely represented in the pig, with 
their nearly identical coronary vasculature making pigs ideal for the study of ischemia-
reperfusion and coronary stent technology[167]. It is desirable to use more closely related 
species like non-human primates [37]. Baboon and other Old World primates [169-171] 
have mostly similar haemostatic system to that of humans. Baboons are also 
immunologically closest to humans[172]. However, according to regulations, these high 
level animals are more protected from animal study usage.  Because of possible severe 
pain or even further sacrifice of these animals, it tends to have more strict regulations of 
animal use. In the U.S., under the provisions of the Animal Welfare Act and the National 
Institutes of Health's (NIH) Guide for the Care and Use of Laboratory Animals (the 
Guide), any procedure can be performed on an animal if it can be successfully argued that 
it is scientifically justified. 
It has been noted that the wound healing capability of human seems to be less 
efficient than common animals. Although these models approximate well human graft 
implantation, the host endothelial proliferation/migration is very different from what is 
observed in humans. The capability of human in vivo re-endothelialization of implanted 
vascular grafts is very poor and often limited to the anastomotic regions (trans-
anastomotic endothelialization) [37]. This is different from what is observed in several 
animal models. Baboon, dog, pig and calf are all able to form a complete tissue lining 
over the inner aspect of arterial prostheses, which is of apparent difference to humans 
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[116, 173]. Thus, ignoring this fundamental difference between common animal models 
and human, would lead to wrong conclusions regarding patency [37]. Baboons seem to 
be of better choice because they demonstrate incomplete endothelialization of ePTFE that 
characterizes human implants [169]. Senescence is another factor affecting the degree of 
in vivo endothelialization. Young animals generally have better wound healing response 
with higher degree of re-endothelialization capability. An alternative to circumvent this 
pitfall is the “loop isolation model” proposed by our collaborator Dr. Peter Zilla of South 
Africa. By insertion of short separation segments of ePTFE grafts between the target 
vascular graft and host arteries, the rapid trans-anastomotic endothelialization will be 
limited to the separation segments. This would help better evaluate the normal wound 
healing response in real human clinical setting. 
  
7.2 Materials and Methods 
In collaboration with Dr. Tetsuji Yamaoka of Japanese National Cardiovascular 
Research Center (Osaka, Japan), 0.15% PGG-fixed elastin scaffolds made from 
decellularization of porcine carotid arteries was implanted into mini pig at the carotid 
position in end-to-end fashion.  Tubular elastin scaffolds were made from fresh porcine 
carotid arteries, decellularized using 0.1M sodium hydroxide method as previously 
described, stabilized with 0.15% PGG, followed by six days of PBS long wash and 50% 
serum/DMEM neutralization for 24h, finally sterilized with 70 % ethanol and stored in 
sterile PBS. Grafts were prepared in Clemson sterilely and shipped to Japan in couple of 
days. Animal study was performed by vascular surgeon at Japanese Cardiovascular 
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Research Center in Osaka, Japan. Lab animal use and care regulations were strictly 
followed.  After implantation, the pigs were kept for 3 months until sacrifice.  
 
 
Fig. 40 0.15% PGG-stabilized Biological Acellular Tissue Scaffold Implanted into Pig 
Carotid in End-to-end Fashion. 
 
Alternative Scaffolds 
We also established collaboration with Dr. Peter Zilla of South Africa. We 
prepared an alternative scaffold of smaller caliber from decellularization of porcine renal 
arteries. Fresh renal arteries harvested from local slaughter house were dissected from pig 
kidney. The decellularization method was modified from the method for carotid arteries. 
0.1M sodium hydroxide solution treatment at 37˚C for 3 hours, instead of 24 hours used 
in carotid protocol, would suffice to remove cellular components from fresh renal tissues. 
Decellularized renal arteries were further stabilized with 0.15% PGG in order to render it 
more resistant to rapid in vivo biodegradation. We also performed a series of fundamental 
study such as mechanical properties, resistance to in vivo enzymatic degradation etc. as 
we did with carotid artery. Tubular vascular scaffolds were prepared sterilely and stored 
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in sterile PBS then shipped to Cape Town, South Africa. Animal surgery was performed 
by local vascular surgeons. PGG-fixed grafts were implanted into rat, sutured to rat 
abdominal aorta in end-to-end fashion. Acknowledging the fact that in vivo spontaneous 
endothelialization in human is poor in contrast to that was seen in animal models, we plan 
to utilize Dr. Zilla’s “loop isolation model[37]” to better simulate would healing response 
in human. In brief, two low porosity ePTFE segments will be positioned in between 
animal host artery and our prepared scaffold. 
 
7.3 Results 
Animal study 1: Carotid artery vascular graft implantation in mini pigs 
0.15% PGG-fixed tubular elastin scaffolds were first tested in Osaka, Japan in late 
January 2010 (Fig. 40). Three months post implantation, animal was sacrificed and the 
vascular graft was retrieved. The graft got occluded and it became hardened as felt by 
touch. In order to make sure if the graft calcified, the occluded graft was analyzed with 
micro-CT scan and the result did not show any calcification in the graft (Fig. 41). Thus, 
the occlusion might be due to thrombosis in the graft.  
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Fig. 41 Examination of Explanted Scaffold from Pig Carotid Artery Model. Explant of 
pig carotid artery model 3 months post-implantation. Graft occluded due to 
possible thrombosis; micro CT scan did not show sign of calcification. 
 
Characterization of alternative decellularized porcine renal artery scaffolds 
For our alternative decellularized porcine renal artery scaffolds, characterization 
data showed that 3 hours of 0.1M sodium hydroxide treatment resulted in efficient 
decellularization (Fig. 42, 43).  Decellularized renal artery scaffolds had good mechanical 
properties in burst pressure and vascular compliance. Decellularized renal arteries 
demonstrated high burst pressures 1800±165 mmHg, with the values close to that of fresh 
tissue (~2000 mmHg). The vascular compliance (Fig. 44) values of 0.15% PGG-fixed 
grafts were also favorable (~1.4%); close to that of fresh arteries (~2%). Porcine renal 
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artery has very different ratio of collagen/elastin composition when compared to carotid 
artery which has more elastin content. From collagenase/elastase digestion study (Fig. 
45), we knew that renal artery is mostly composed of collagen; with much fewer elastic 
fibers present. Moreover, PGG stabilization rendered this collagen-rich scaffold more 
resistant to collagenase degradation.  
 
(a) (b)
(c) (d)
(e) (f)
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Fig. 42 Histological Examination of Fresh (left column) and Decellularized Renal Artery 
(right column); (a),(b) in H&E stain, (c),(d) in Trichrome stain, (e),(f) in VVG 
stain. Decellularization was complete after 3 hours of 0.1M sodium hydroxide 
treatment 
 
 
 
Fig. 43 DNA Quantification by Agarose Gel Electrophoresis shows that decellularization 
was nearly complete. 
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Fig. 44 Vascular Compliance Test of Decellularized Porcine Renal Artery Scaffolds. 
Multiple measurements of vessel diameter at 80/120 mmHg were used to 
calculate compliance value. 
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Fig. 45 Enzyme Resistance Study of PGG-stabilized Decellularized Porcine Renal Artery 
Scaffolds. Greater mass loss after collagenase digestion implied that renal artery 
has much more collagen content; secondly, PGG stabilization effectively 
protected tissue against enzymatic degradation. 
 
Animal study 2: Rat abdominal aorta vascular graft implantation (alternative 
renal artery scaffold) 
Dr. Peter Zilla and his research group implanted several grafts into rat abdominal 
aorta position in end-to-end fashion (as indicated by arrows in Fig. 46). Preliminary data 
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showed the first graft got occluded, possibly due to thromboses formation. There was no 
sign of calcification. We did observe host cell repopulation activities within the graft. 
Cell infiltrated from the adventitial side toward vessel lumen demonstrated that our 
scaffold is biocompatible and inductive to host cell repopulation. In order to improve its 
hemacompatibility, a strategy of heparin immobilization using EDC-NHS chemistry was 
adapted. Additional PGG-treated, elastin-derived vascular grafts (EDVG) prepared by the 
PI were implanted in the rat infra-renal aortic model at the University of Cape Town as 
direct end-to-end grafts (Fig. 47a, arrows point at anastomoses). In one series of studies, 
grafts were covalently heparinized using diamine-enhanced carbodiimide chemistry 
before implantation. Grafts explanted after 7 days showed good patency (Fig. 47b) with a 
thin thrombus layer attached to the luminal wall (Fig. 47c). Histology showed incipient 
cell infiltration mainly via the adventitial aspect (Fig. 47d, black arrows) and good 
preservation of the graft architecture, including the internal elastic lamina (Fig. 47e, black 
arrow) and the adventitial elastin / collagen network (Fig. 47e, orange arrow). In another 
study, grafts explanted after 2+ weeks exhibited high levels of repopulation with host 
cells (Fig. 47f,g, arrows) and strong angiogenic potential (Fig. 47f, dashed circles, g, 
immunofluorescence staining for a-smc-actin, green circles). Latest result showed that 
this layer of immobilized heparin did help prevent thrombosis. The graft remained patent 
though 7 days. More experiments are in progress in South Africa.  
 Fig. 46 Decellularized P
anastomosed in rat abdominal aorta in 
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orcine Renal Artery Scaffold for Rat Surgery. Scaffold was 
end-to-end fashion. 
 
 108
 
Fig. 47 Heparinized Renal Artery Scaffold for Rat Surgery. Heparinized scaffolds were 
anastomosed to rat abdominal aorta in end-to-end fashion and explanted 7 days 
post implantation. a = anastomoses of graft to host artery, b, c = macroscopic 
views of explanted scaffold, d and f = H&E stain, e = ELMAS stain, g, blue 
DAPI stain for nuclei. d-g, Original magnification x200.      
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7.4 Discussion 
We had planned an animal surgery using rabbit carotid model to validate the 
functionality of our novel elastin scaffolds in 2008; however, the experiment did not 
succeed due to the dimension mismatch of the tubular scaffolds and rabbit carotid artery. 
Then we decided to switch to mini-pig model, for it may have comparable sizes to our 
elastin scaffolds. Collaboration with Dr. Yamaoka in Japan enabled us doing first mini 
pig surgery in 2010. The first experiment showed that the graft got occluded three months 
post implantation. However, the graft did not calcify. The probable reason for occlusion 
is thrombosis. The prepared grafts for implantation were not endothelialized, nor being 
surface-treated beforehand. Thus, it is not too surprising that there was blot clot 
formation which is one major reason for acute failure for vascular grafts. We encountered 
similar problems with our alternative renal scaffolds. First experiment showed that 
occlusion due to thrombosis resulted in failure of the graft. Advanced assay showed that 
there was no calcification. Based on this, we tried to improve hemacompatibility by 
immobilization of heparin onto the luminal surface of grafts. Latest study showed 
encouraging results. The graft remained patent after 7 days in vivo. In the Future, grafts 
shall be seeded with confluent endothelial cells on the vessel lumen in order to provide 
inherent hemacompatibility. The two animal studies so far were done in either Japan or 
South Africa. Grafts were prepared and sent overseas for implantation. Ideally, these 
grafts shall have been pre-endothelialized and pre-conditioned on site before animal 
surgery. We shall be continuing to improve and optimize seeding techniques and pulsatile 
bioreactor so that we could do better evaluation of our novel elastin grafts. 
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7.5 Conclusions 
We tested the functionality of PGG-fixed grafts with mini pig carotid model and 
rat abdominal aorta model. Both experiments showed that our tubular scaffolds had 
sufficient mechanical strength to withstand pulsatile arterial blood flow. In addition, 
preliminary data showed that PGG seemed to greatly reduce ectopic calcification. Both in 
mini pigs and rats animal experiments did not show signs of calcification. We also 
examined scaffold calcification in previous in vivo biocompatibility test (rat 
subcutaneous model) of up to 8 weeks. PGG-fixed scaffolds had very low calcium 
content when compared to non-PGG-fixed scaffolds. Elastin is well known for its 
tendency to calcify, and this would result in hardening of vascular graft and lose of 
elasticity. With PGG treatment, calcification was greatly reduced. Although the 
mechanism on how PGG reduces in vivo calcification is not yet understood, we think 
PGG holds great potential in cardiovascular tissue engineering applications. 
Our novel 0.15% PGG-fixed grafts also demonstrated being very inductive to host 
cell repopulation in the South Africa animal study. This implies remodeling activities 
within the scaffolds. Further experiments to identify the cell type and to evaluate ECM 
degradation/deposition are needed. Overall, we novel PGG-fixed biological vascular 
grafts possess good mechanical properties and suturability; the grafts remained patent up 
to 7 days and had remodeling potential.  
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CHAPTER EIGHT 
RECOMMENDATIONS 
 
The ultimate test of vascular graft, before clinical trial, is using animal circulation 
model to demonstrate its functionality and patency. Due to the restraint of budget for 
animal study, we do not have the luxury of time and accessibility to many large animals 
so as to get statistical power for the experiment. Currently, we only have few preliminary 
data from collaboration with researchers in Japan and South Africa. For now, this is not 
sufficient to assertion of the validity of our novel biological elastin-based vascular graft. 
In the future, we shall seek for advanced opportunities of performing more animal 
studies.  
Secondly, we shall plan to pre-endothelialize the luminal surfaces of the vascular 
grafts before implantation. The grafts sent to Japan or South Africa collaboration partners 
were not seeded endothelial cells. Thus it is not too surprising that the grafts got occluded 
due to probable thrombosis. We have recently developed a custom-made cell seeding 
device, which is capable of seeding the luminal surface of grafts in a synergistic fashion. 
For best seeding results, we need to have very high endothelial cell seeding density to 
start with. Our seeding density seemed too low and that is probably why we did not have 
very good cell coverage. Primary endothelial cells are not very proliferative, and it is hard 
to have sufficient amount of cells to seed couple of grafts at one time. For future 
experiments, he or she needs to expand the number of endothelial cells as many as 
possible. There is something needs to improved for the seeding device as well. Mounting 
and hook-up of grafts to the seeding device were not easy. When using the Luer-lock 
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mechanism to twist both ends of graft onto/off the seeding device, grafts might be twisted 
as well. And due to the small dimension of the seeding device, “twist on/off” was not 
easily maneuverable. 
Thirdly, for our first generation pulsatile vascular bioreactor design, there is still 
much to improve. For example, the dimensions of orifices on the bioreactor and of the 
accessories were too small. We finally realized that the flow rate was not large and this 
indirectly contributed to the small fluid shear stress value in the system. It is apparent that 
bigger opening and larger tubing/manifold are needed for the next generation of 
bioreactor design. Moreover, our current experimental setup could not fit in single cell 
incubator; we used two incubators stack on one the other in order to get pressure 
fluctuation close to physiological range. However, plugging and unplugging tubing 
connecting the bioreactor and two culture media reservoirs would increase the risk of 
getting bacterial contamination. We only ran the endothelial cell retention under pulsatile 
flow study for 20 hours, and this is probably not long enough. If we could solve this 
issue, we would be able to extend the usage of this pulsatile shear flow; for example, we 
could increase the magnitude of shear stress gradually in order to “train” the endothelial 
cell layer to better assure of cell retention when subjected to physiological shear flow.    
According to the Hagen-Poiseuille formula, we know that the magnitude of fluid 
shear is associated with flow rate, fluid viscosity and inner diameter of tube. The shear 
stress value in our experiment was not close to physiological level in arteries. The way to 
increase the shear stress within our system is either to increase flow rate and/or fluid 
viscosity. As mentioned earlier, larger size of tubing/orifices is needed for the 
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improvement of the bioreactor. In addition, using more viscous culture medium may be 
favorable. This might be achieved by adding starch or some biological polymers. Another 
way of designing a pulsatile bioreactor is to connect the heart valve bioreactor to the 
existing vascular bioreactor. The heart valve bioreactor serves as “pulsatile flow source”, 
and this would eliminate the use of pinch valve. Moreover, there is no need to have two 
separate media reservoirs, and this would simplify the experimental setup; the whole 
system could possibly fit in a cell incubator and thus avoid many problems we had in our 
two-reservoir system. 
In summary, we have demonstrated the feasibility of our novel biological elastin-
based scaffold as a promising candidate for vascular surgery. Although many of the 
procedures are not optimized, such as endothelialization of luminal surface of grafts, the 
design of bioreactor and the experimental parameters, these could be improved with the 
possibility of moving to the stage of human clinical trial based on the success of animal 
circulation studies. Animal model study is very costly and there are several aspects need 
to be considered. We had difficulties in the first try using rabbit carotid model in 2008: 
dimension mismatch between the graft and host artery, insufficient fund to switch to large 
animal model like mini pigs etc. All in all, we learned many valuable lessons from these 
activities in every aspect of this vascular project. We shall keep on improving and 
approach the ultimate goal in a timely fashion. 
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